

Meeting of BNSSG ICB Board

Date: Thursday 6th July 2023 Time: 0900-1500 Location: Microsoft Teams

Agenda Number:	7.1	
Title:	Quality and Performance Report – Month 1	(April data)
Confidential Papers	Commercially Sensitive	No
	Legally Sensitive	No
	Contains Patient Identifiable data	No
	Financially Sensitive	No
	Time Sensitive – not for public release at this time	No
	Other (Please state)	No
Purpose: Discussion & Ir	nformation	
Key Points for Discussio	n:	

The 2 attached reports provide an overview of April 2023 data to cover Month 1 activity for quality and performance. A summary is provided below.

The committee are asked to note the following areas.

Quality (Appendix 1)

Healthcare Associated Infections

Integrated Care Boards (ICBs) and secondary care providers threshold levels for 2023/24 were released in May 2023 by NHS England and NHS Improvement. Slide 6 shows these values for the below reported data.

- **C. Difficile** In April 2023, 26 cases were attributed to BNSSG ICB which is an increase of 12 against the previous month. The system has seen an improving picture for reported cases of C Diff over the last 5 months with HOHA cases showing a similar decline during this period. The BNSSG position for C Diff per 100k of population (2.46) remains above the Southwest and National average. The CDI working group continues to work with the system and regional partners to understand the drivers behind these numbers.
- **E.coli** In April 2023, 37 cases of E. coli bacteraemia cases (an increase of 12 from March) were assigned to BNSSG ICB. The BNSSG rate per 100k of population (3.50) continues to be below the average of 5.11 for the Southwest regions and 5.31 for England.

- **MSSA** (Methicillin-resistant Staphylococcus aureus) In April 2023, 12 cases of MSSA bacteraemia were assigned to BNSSG ICB which is 1 case higher than the previous month. Case activity for MSSA per 100k of population (1.13) continues to be below the Southwest average of 1.75 and the national average of 1.67.
- **MRSA** (Methicillin-resistant Staphylococcus aureus) In April 2023, there was 1 case of MRSA bacteraemia assigned to BNSSG ICB, which is 2 lower than the numbers reported in March 2023. The 1 reported case in April was attributed to 1 x hospital acquired (HOHA). Case activity for MRSA per 100k of population (0.09) is below the Southwest and National average, although it should be noted that there is a zero tolerance for numbers of reported MRSA cases.

The table below shows the numbers of reported cases by month, by infection and the numbers of reported cases YTD against the threshold.

Infection	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Threshold to Date	Cases YTD	Threshold		21/22 FYTD
C. difficile	26												24	26	284	23	26
E. coli	37												42	37	505	42	46
Klebsiella spp	10												12	10	147	11	14
MRSA	1												0	1	0	4	1
MSSA	12													12		16	19
Pseudomonas aeruginosa	5												5	5	60	3	7

Significant events/themes and trends and Learning

Overall, the top three themes being identified as causal factors from the investigation process for general SE's are 1) Communication /MDT 2) Risk Assessments and care planning and 3) Care delivery.

A deep dive is underway to understand the drivers behind the significant increase in care delivery events which have been seen. The outcome of the deep dive will be reviewed at the July 2023 learning panel which is led by the ICB and attended by system partners. The findings will then be shared at SQG in July 2023.

Learning Disability and Autism Adults

- There continues to be an increase in CTR related activity, 51 Professionals meetings/ MDT's/ Safeguarding/Discharge planning meetings for adults.
- 3 individuals are identified as Delayed Discharge from ICB cohort, 1 individual identified as Delayed Discharge from Secure bed base. There are 4 individuals in the community on Section 17 leave.

СҮР

- CETR and LEAP activity has been reduced significantly in last 2 months which aligns with the keyworker team being fully operational.
- The C(E)TR team are providing additional support to the Keyworker Team to triage requests.

Performance (Appendix 2)

The performance report for this month is based on April 2023 information.

Urgent Care

- BNSSG performance narrowly missed the 75% A&E 4-hour performance standard.
- Ambulance handovers remain on track and met trajectory in April. Current performance is showing that June average handovers, despite increases in demand before industrial action is below trajectory. UHBW are starting a perfect week on ambulance handovers week commencing 19.06.23.
- Performance remained steady over the industrial action days in June (14-17) but demand across the country did increase mainly due to heat and did impact on urgent care performance. However, BNSSG did well to hold performance.
- The first service delivery unit for urgent care will take place in week commencing 19.06.23 and will also review the 29Forward report on urgent care.

Elective Care

- Weekly scrutiny of all long waits and detailed returns to NHSE and national team continues. System position on long waits relates to complex patients where mutual aid even with London providers is proving not to be successful. Industrial impact will be calculated by end of June but will have created further backlog and starting to impact on >65 week waiters.
- Endoscopy remains the biggest challenge in diagnostics to the system. Focussed action plans in implementation at both trusts including insourcing and outsourcing capacity. System working to try and conclude CDC negotiations.
- Industrial action impacting on cancer services in the short term for 63+ day waits but is being closely monitored and additional sessions being put on where the workforce is available.
- FDS is the key target this year and the improvements are being made.
- Key risk is skin pathways and an options appraisal in relation to tele dermatology is being worked up to present back to the Gateway panel.

Mental Health

- Small increase in dementia diagnosis rate which is positive.
- SMI annual checks significant improvement 62.2% ahead of the standard of 60.0%.
- CYP mental health access is steady and improving from pre-covid but below the standard of 34%.
- IAPT is recovering above 50% but below the planned roll out pace.
- Out of area placements has reduced but more recent data is showing an increase.

Recommendations:	To note the reports including any risks, mitigating actions and responsibilities as appropriate.
Previously Considered By and feedback:	Not previously considered
Management of Declared Interest:	None declared



Risk and Assurance:	The report and appendices provide an update to the Board in relation to key risks to performance and quality within the system and highlight supporting mitigations which are in place. Previously discussed at Outcomes, Quality and Performance Committee 28.06.2023
Financial / Resource Implications:	None referenced
Legal, Policy and Regulatory Requirements:	None referenced
How does this reduce Health Inequalities:	Not referenced
How does this impact on Equality & diversity	As above
Patient and Public Involvement:	Not applicable
Communications and Engagement:	The reports are provided to the ICB Board for information and discussion.
Author(s):	Caroline Dawe - Deputy Director of Commissioning (Performance Improvement) Gary Dawes - BI Manager, Performance, BNSSG ICB Sandra Muffett Head of Patient Safety & Quality, BNSSG ICB Michael Richardson, Deputy Director of Nursing and Quality, BNSSG ICB
Sponsoring Director / Clinical Lead / Lay Member:	Rosi Shepherd, Chief Nursing Officer, BNSSG ICB Lisa Manson, Director of Performance and Delivery, BNSSG ICB





Bristol, North Somerset and South Gloucestershire

Integrated Care Board

BNSSG Quality Report

June Report on Month 1 (April data) 2023/24

Developed in June 2023 with contributions from across the Quality and Patient Safety Team.

Quality Report – Health Care Acquired Infections (HCAI) Summary Reporting Period – Month 1 2023/24 – April data Information Source and date of information – UK Health Security Agency (UKHSA), ICS HCAI Lead

0.95

2.04

Kleb spp

1.16

1.26

Infecti	on	Rolling 1 Tre	2 Month end	2023/2	24 Thresh	olds	2023/ Y TI	24	2022/23 Position Month 1	2021/ Positi Monti	on
C. diffi	cile	~	\sim	24 0	26	284	26	6	23	26	
E. co	bli	\sim	\sim	42 0	37	505	37	7	42	46	
MRS	Ā	\sim	\mathcal{V}	8	1	1	1		4	1	
MSS	A	۶	~~				12	2	16	19	
Klebsiell	a spp	\sim	m	12 0	10	147	10)	11	14	
Pseudom aerugir		\sim	$\label{eq:label}$	5	5	60	5		3	7	
Patas par		•		S	outh Wes	t Posit	tion				
Rates per 100k	BSW	BNSSG	Kernow	Devon	Dorset	Glo	s So	merset	SW	England	BNSSG
C. diff	2.24	2.46	1.83	1.73	1.95	3.84	4	2.18	2.26	2.00	6
E. coli	3.98	3.50	7.81	6.75	5.00	2.9	5	6.20	5.11	5.31	2
MRSA	0.10	0.09	0.00	0.16	0.24	0.0	0	0.00	0.10	0.11	4
MSSA	1.33	1.13	2.49	2.20	1.59	1.7	7	2.01	1.75	1.67	1
Pseud A	0.82	0.47	1.16	0.24	0.61	0.0	0	0.67	0.53	0.56	3

1.95

1.77

1.17

1.47

1.51

1

Quality Report – Health Care Acquired Infections (HCAI) ICB Overview Reporting Period – Month 1 2023/24 – April data Information Source and date of information – UK Health Security Agency (UKHSA), ICS HCAI Lead	
Performance for April 2023	Risks/Assurance Gaps
CDI = 26, HOHA = 7 (NBT - 1, UHBW - 6), COCA = 6, COHA = 7, COIA = 6	The SPC diagrams have switched from a monthly value to a 12-month
E. coli = 37, HOHA = 7 (NBT - 4, UHBW - 3), COCA = 24, COHA = 6	rolling value. This is to remove the variation we find each month and
MRSA = 1, HOHA = 1 (NBT - 0, UHBW - 1), COCA = 0, COHA = 0	to limit the impact of seasonality on the process. Targets/Thresholds
MSSA = 12, HOHA = 4 (NBT - 1, UHBW – 2, Other -1), COCA = 6, COHA = 2	set are those set for 23/24.
Klebsiella spp = 10, HOHA = 2 (NBT - 1, UHBW - 1), COCA = 8, COHA = 0	
Pseudomonas aeruginosa = 5, HOHA = 3 (NBT - 1, UHBW - 2), COCA = 2, COHA = 0	All infection types are improving relative to current upper and lower
	limits, many of them trending lower than a spike during the
HOHA – Hospital Onset, Hospital Associated	pandemic. MSSA is an exception with a continued increase over the
COHA – Community Onset, Hospital Associated	previous 6-month period.
COCA – Community Onset, Community Associated	
COIA – Community onset, Indeterminate Association	On 5 May 2023, the World Health Organisation declared the
	pandemic to no longer be declared a global emergency. We will
BNSSG Annual Standard	reassess in the future if this has had an impact on the number of
	cases in BNSSG to require a rebase of the process limits and average.
 Integrated Care Boards (ICBs) and secondary care providers threshold levels for 2023/24 were 	
released in May 2023 by NHS England and NHS Improvement.	Special focus on Hospital Onset HCAI this month.


Both ICB and secondary care threshold levels are specified in the below table:

Infection	Apr	Мау	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Threshold to Date	Cases YTD	Threshold		21/22 FYTD	*The table provides
	00												24	00	004	00	00	the monthly ICB
C. difficile	26												24	26	284	23	26	assigned cases as
E. coli	37												42	37	505	42	46	well as the year-to-
Klebsiella spp	10												12	10	147	11	14	date total. The 2 final
MRSA	1												0	1	0	4	1	columns are our benchmark against
MSSA	12													12		16	19	the 2022/23 and
Pseudomonas aeruginosa	5												5	5	60	3	7	2021/22 positions.

Commentary

- MRSA- Zero tolerance has not been achieved. There was 1 case in April (HOHA).
- CDI- The 26 cases are currently categorised as follows: Continuing Infection (1), New infection (19), Repeat/Relapse (1), and Unknown (5).
- E.coli- the majority of the 44 cases continue to be Community Onset (30).


Quality Report - Healthcare Acquired Infections - Supporting Analysis





BNSSG ICB Assigned C. difficile Cases Since Apr 2021

Hospital Onset CDI has a variation of special cause concern low, with a decreasing trend below the lower control limit since the previous rebase.

BNSSG Wide CDI has a variation of special cause concern low, trending towards the lower control limit since the previous rebase. Things are improving but the 23/24 target lies between the upper and lower bounds, the processes is expected to hit or miss this target.









BNSSG ICB Assigned E. coli Cases Since Apr 2021


Hospital Onset E. coli has a variation of special cause concern low, trending below the average since Apr 21 and currently below the lower process limit.




BNSSG Wide E. coli has a variation of special cause concern low, trending below the lower control limit since the previous rebase. Things are improving but the 23/24 target lies between the upper and lower bounds, the processes is expected to hit or miss this target.




Quality Report – Healthcare Acquired Infections - Supporting Analysis






Hospital Onset MRSA has a variation of common cause and has is not changing significantly since a rebase in Apr 22.

BNSSG Wide MRSA has a variation of special cause concern low, trending below the lower control limit since the previous rebase. Things are improving but have already exceeded threshold of 0 for 23/24.






6

BNSSG ICB Assigned MRSA Cases Since Apr 2021


30





BNSSG ICB Assigned MSSA Cases Since Apr 2021

Hospital Onset MSSA is showing a variation of a concerning nature, a sharp increase over previous months.

BNSSG Wide MSSA has a variation of special cause concern high, trending above the upper control limit since the previous rebase. The past 3 months have decreased but this trend needs to continue.









The metrics that have been summarised in the above table have been selected as the most significant in relation to the quartile position and position above the national median. Their purpose is to encourage further investigation and is not meant to represent the definitive position of what is occurring within the system. In-depth details are provided in <u>Model Hospital</u>.

Quality Report - Healthcare Acquired Infections – Supporting Analysis




BNSSG ICB Assigned Klebsiella spp Cases Since Apr 2021

Hospital Onset Klebsiella spp is showing a variation of special cause concern low, trending below the average since Sep 22 and currently below the lower process limit.




BNSSG Wide Klebsiella spp has a variation of special cause concern low as it continues decreasing from its spike in 2021. At this rate, however, it is not expected to hit the 23/24 threshold target.




20...

Quality report – Healthcare Acquired Infections - Supporting Analysis


BNSSG ICB Assigned Pseudomonas aeruginosa Cases Since Apr 2021






Hospital Onset Pseud A is showing a variation of special cause concern low, trending below the average since Jul 22 and currently below the lower process limit, although recently increasing.


BNSSG Wide Pseud A has a variation of special cause concern low, trending below the lower control limit since the previous rebase. The trend is decreasing however data from the previous 2 years suggests the 23/24 threshold won't be met.







Quality report – Healthcare Acquired Infections - SPC Grid



H Special (Concer variat	Cause Specia ming Imp	al Cause roving fation	Consistently	Hit and miss target subject to random	Consistently fail target
	Variatio	n	A	ssurance	e
C	HL	HL	?	P	F
Common cause – no significant change	Special cause of concerning nature or higher pressure due to (H)igher or (L)ower values	Special cause of improving nature or lower pressure due to (H)igher or (L)ower values	Variation indicates inconsistently passing and falling short of the target	Variation indicates consistently (P)assing the target	Variation indicates consistently (F)alling short of the target

SPC Xmr diagrams were made using the NHS Plotthedots R Package. The icons above represent the meaning as above.

In terms of variation in the caseload, the SPC grid means:

- All infection types have an improving nature, mostly due to historical increases during the pandemic that the rates are now lowering from
- MSSA, not featured, has an increasing trend.


In terms of assurance against the threshold, this means:

- The process limits on SPC charts indicate the normal range of numbers you can expect from your system or process. **If a target lies within those limits then we know that the target may or may not be achieved.** The closer the target line lies to the mean line the more likely it is that the target will be achieved or missed at random. This is the case for C. diff and E. coli which have new lower targets for 23/24 – further improvement is required to be assured they will be reached.
- MRSA has failed the threshold for 23/24 (0 cases). At the current rates Klebsiella spp and Pseud A will fail the 23/24 threshold.
- MSSA is not included as NHSE does not set a threshold.

Nursing & Quality – Themes and Trends Highlights Reporting Period – Month 1 2023/24 – April data

Information Source and date of information – Themes tracker 15/06/2023

The table below highlights the top-level themes identified through the investigation process for reported events and detailed in the submitted investigations over the last 15 months, when this data collection commenced.



Across the system, it is noted that the top three themes remain


- Communication/MDT
- Risk Assessment and Care Planning
- Care Delivery


To understand the drivers behind the patient safety events related to these themes, "deep dives" are being undertaken and the outcomes will be shared in the coming months.


Nursing & Quality – SI Themes and Trends across BNSSG partners Reporting Period – Month 1 2023/24 – April data

Since March 2022, when this data collection commenced, the running total of Serious Incident investigations reviewed by the Quality team is 228, please see table below for breakdown by type of incident. The graphs on the right show the themes identified through the reviews of the investigation reports of the top three SI types.

	Number of investigation reports reviewed
Serious Incident Types	per SI type
Pressure Injury	51
Treatment delay	26
Obstetric	23
Slips/trips/falls	21
Suspected suicide	19
Diagnostic	19
Sub-optimal care	15
Medication	13
Suspected self-inflicted harm	7
Wrong site surgery	6
Surgical procedure	5
Aggressive behaviour	4
HCAI/Infection control	3
Unexpected death	3
Medical equipment	2
Homicide	2
Alleged assault of patient	1
Misplaced naso or oro-gastric tubes	1
Retained object post procedure	1
Alleged assault of patient	1
Blood product/transfusion	1
Failed discharge	1
Screening issues	1
Wrong implant/prosthesis	1
Failure to obtain appropriate bed for child	1








Nursing & Quality - Funded Care - Assuring Transformation –Learning Disability and Autism Reporting Period – Month 1 2023/24 – April data

Performance/Data for 2022-2023 Adults



Highlights

Adults

- There continues to be an increase in CTR related activity, 51 Professionals meetings/ MDT's/ Safeguarding/Discharge planning meetings for adults.
- ICB commissioned placements remain below trajectory, however SWPC (Secure) placements remain above the trajectory to reach the Long Term Plan target.
- 3 new admissions to AWP beds no individuals were known to the team and no pre-admission CTR's were requested.
- 2 individuals are being managed through the court of protection (1 Community, 1 inpatient).
- 3 individuals are identified as Delayed Discharge from ICB cohort, 1 individual identified as Delayed Discharge from Secure bed base. There are 4 individuals in the community on Section 17 leave.

CYP

- CETR and LEAP activity has been reduced significantly in last 2 months, which aligns with the keyworker team being fully operational.
- The C(E)TR team are continuing to provide additional support to the Keyworker Team to triage requests.



Bristol, North Somerset and South Gloucestershire Integrated Care Board

BNSSG Performance Report

June 2023

Created by

BI Performance Team

Contents

1. Executive Summary

2. Performance

- 2.1 South West Performance Benchmarking
- 2.2 Urgent and Emergency Care Summary
 - UEC Key Performance Measures
 - Care Homes Occupancy Report
- 2.3 Planned Care Summary
 - RTT & Diagnostics & Cancer Key Performance Measures
- 2.4 Mental Health, Learning Disabilities and Autism Key Performance Measures
- 2.5 Sirona Adults Community Services 18 Week Performance
- 2.6 Children's Performance CYP Emergency Department Overview

3. Summary Scorecards

- 3.1 BNSSG ICB
- 3.2 NBT
- 3.3 UHBW
- 3.4 Non-Acute Providers

1 Executive Summary

- Overall, BNSSG Trusts' 4hr A&E performance worsened from 73.9% to 68.5% in May and is better than the national average for Type 1 EDs of 60.4%.
- For planned admissions, the total waiting list size for the BNSSG population worsened from 85,444 in March to 99,101 in April. BNSSG performance of 63.8% was ranked 19th out of 42 ICBs nationally (down from 8th) and ranked 4th out of 7 ICBs in the South West (down from 2nd in March).
- The number of BNSSG patients waiting 52 weeks or more for planned treatment increased from 4,124 in March to 6,022 in April 6.1% of the total waiting list. The number increased at both NBT and UHBW. The BNSSG position is driven mainly by waits at UHBW (3,476) and NBT (2,194), with the remaining 352 breaches split across 53 other providers. Focused work to facilitate elective recovery ambitions are being implemented.
- The number of BNSSG patients waiting over 65 weeks increased from 973 in March to 1,409 in April. The number increased at both NBT and UHBW. The BNSSG position is driven mainly by waits at UHBW (833) and NBT (470). The remaining 106 breaches are split across 24 other providers, with the majority at Nuffield Health Bristol (45).
- The number of BNSSG patients waiting over 78 weeks increased from 88 in March to 122 in April. The number increased at UHBW but fell at NBT. The BNSSG position is driven mainly by waits at UHBW (53) and NBT (49). The remaining 20 breaches are split across 5 other providers, with the majority at Nuffield Health Bristol (14).
- The number of BNSSG patients waiting over 104 weeks increased from 6 in March to 7 in April. The number decreased at UHBW but increased at NBT. The BNSSG position is driven by waits at NBT (6) East Kent Hospitals (1).
- 2 week wait cancer performance worsened in April to 42.9% for the BNSSG population. Performance worsened at both NBT and UHBW. The 93% national standard has not been achieved at population level since June 2020.
- 28 day faster diagnosis standard for BNSSG cancer patients worsened in April to 66.1% for the BNSSG population. Performance
 worsened at both NBT and UHBW. The 75% national standard has not been achieved at population level since reporting started in April
 2021.
- 62 day referral to treatment time for BNSSG cancer patients worsened in April to 61.1.9%. Performance improved at UHBW but worsened at NBT. The 85% national standard has not been achieved at population level since April 2019.

2.1 South West Performance Benchmarking 1

					Performar	nce/Activity				South West Ranking									e
Measure	Standard	Recent Period	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	National	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	Rank Last Month	
Diagnostics (Waiting 6+ Weeks)	1%	Apr-23	40.71%	22.47%	11.03%	38.82%	25.15%	23.12%	34.59%	27.56%	7	2	1	6	4	3	5	3	->>
A&E 4 Hour Performance	76%	May-23	71.57%	79.38%	75.01%	79.08%	78.65%	74.93%	64.51%	73.96%	6	1	4	2	3	5	7	2	•
A&E 12 Hour Trolley Waits	0	May-23	200	74	1113	467	16	474	829	31,494	3	2	7	4	1	5	6	4	•
RTT Incomplete 18 Weeks	92%	Apr-23	60.25%	54.63%	68.43%	58.26%	60.01%	59.45%	53.83%	58.31%	2	6	1	5	3	4	7	2	•
RTT Incomplete Total		Apr-23	101,512	101,621	79,136	70,189	66,309	99,101	164,062	7,415,352	82.3%	84.4%	53.3%	97.3%	83.9%	94.9%	94.0%	68.0%	4
RTT Incomplete 52 Week Plus	0	Apr-23	4,680	5,680	2,512	4,832	3,007	6,022	13,823	371,111	3	5	1	4	2	6	7	4	•
RTT Incomplete 65 Week Plus	0	Apr-23	980	1,530	417	1,832	886	1,409	4,754	95,135	3	5	1	6	2	4	7		
RTT 52 weeks + (% of waiting list)		Apr-23	4.61%	5.59%	3.17%	6.88%	4.53%	6.08%	8.43%	5.00%	3	4	1	6	2	5	7	4	•
RTT 65 weeks + (% of waiting list)		Apr-23	0.97%	1.51%	0.53%	2.61%	1.34%	1.42%	2.90%	1.28%	2	5	1	6	3	4	7		
RTT 78 weeks + (% of waiting list)		Apr-23	0.03%	0.13%	0.01%	0.65%	0.16%	0.12%	0.69%	0.15%	2	4	1	6	5	3	7	3	->
RTT 104 weeks+ (% of waiting list)		Apr-23	0.00%	0.00%	0.00%	0.08%	0.01%	0.01%	0.07%	0.01%	3	1	2	7	4	5	6	5	->>
Cancer 2 Week (All)	93%	Apr-23	72.48%	64.64%	95.45%	53.09%	60.93%	42.85%	64.87%	77.71%	2	4	1	6	5	7	3	7	⇒
Cancer 2 week (Breast)	93%	Apr-23	87.55%	94.55%	99.00%	20.44%	58.41%	50.00%	85.51%	72.19%	3	2	1	7	5	6	4	6	⇒
Cancer 31 Day Wait First Treatment	96%	Apr-23	88.94%	94.28%	92.36%	88.30%	89.05%	89.18%	89.47%	90.48%	6	1	2	7	5	4	3	2	•
Cancer 31 Day Wait - Surgery	94%	Apr-23	68.35%	79.49%	84.09%	82.50%	71.19%	85.87%	81.53%	76.78%	7	5	2	3	6	1	4	1	→
Cancer 31 Day Wait - Drug	98%	Apr-23	98.55%	95.51%	100.00%	100.00%	99.19%	98.58%	98.74%	97.37%	6	7	1	1	3	5	4	4	•
Cancer 31 Day Wait - Radiotherapy	94%	Apr-23	92.92%	96.84%	93.58%	96.58%	87.23%	98.62%	94.78%	86.32%	6	2	5	3	7	1	4	2	1
Cancer 62 Wait Consultant	N/A	Apr-23	82.43%	72.34%	73.91%	65.22%	83.33%	75.00%	68.97%	74.44%	2	5	4	7	1	3	6	4	1
Cancer 62 Wait Screening	90%	Apr-23	72.73%	66.67%	80.77%	62.16%	75.00%	55.56%	66.67%	67.82%	3	4	1	6	2	7	4	3	4
Cancer 62 Day Wait - GP Referral	85%	Apr-23	65.31%	66.78%	64.08%	65.05%	69.84%	61.14%	62.37%	61.04%	3	2	5	4	1	7	6	5	V
Cancer 28 FDS	75%	Apr-23	70.27%	71.16%	79.20%	68.68%	69.46%	66.12%	76.30%	71.35%	4	3	1	6	5	7	2	4	•

Includes addition of new measure - RTT 65 Week Waits (Operational Plan 23/24)

2.1 South West Performance Benchmarking 2

					Performan	ce/Activity							Sou	uth West	Ranking			Change	
Measure	Standard	Recent Period	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	SWASFT	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	Rank Last Month	
Category 1 - 90th Percentile Duration (hr:min:sec)	00:15:00	May-23	00:17:24	00:15:36	00:17:36	00:21:06	00:20:12	00:13:54	00:17:42	00:17:24	3	2	4	7	6	1	5	1	->>
Category 1 - Average Duration (hr:min:sec)	00:07:00	May-23	00:09:36	00:08:24	00:09:42	00:11:06	00:10:42	00:07:54	00:09:30	00:09:24	4	2	5	7	6	1	3	1	⇒
Category 2 - 90th Percentile Duration (hr:min:sec)	00:40:00	May-23	01:23:24	01:03:30	01:09:06	01:30:54	01:26:48	01:00:06	01:26:00	01:17:24	4	2	3	7	6	1	5	1	⇒
Category 2 - Average Duration (hr:min:sec)	00:30:00	May-23	00:39:30	00:31:24	00:32:36	00:44:00	00:42:24	00:28:06	00:40:12	00:36:42	4	2	3	7	6	1	5	1	⇒
Category 3 - 90th Percentile Duration (hr:min:sec)	02:00:00	May-23	04:56:42	03:26:12	03:12:30	02:51:00	05:34:18	04:18:00	04:59:30	04:18:36	5	3	2	1	7	4	6	4	->
Category 3 - Average Duration (hr:min:sec)		May-23	01:52:18	01:25:00	01:23:00	01:16:18	02:06:42	01:34:42	01:56:18	01:40:18	5	3	2	1	7	4	6	2	•
Category 4 - 90th Percentile Duration (hr:min:sec)	03:00:00	May-23	05:40:24	07:50:12	06:02:54	02:15:48	11:34:18	07:50:36	07:28:12	06:56:48	2	5	3	1	7	6	4	5	♦
Category 4 - Average Duration (hr:min:sec)		May-23	02:09:18	02:18:18	01:54:48	00:49:36	03:41:18	02:37:48	02:36:30	02:23:54	3	4	2	1	7	6	5	5	₩

					Performa	nce/Activity	1						So	uth West	Ranking			Change	
Measure	Standard	Recent Period	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	National	BSW	Dorset	Glos	Kernow	Somerset	BNSSG	Devon	Rank Last Month	
Average speed to answer calls (in seconds)	20	Apr-23	89	21	456	214	257	151	384	236	2	1	7	4	5	3	6	4	♠
% Triaged Calls receiving Clinical Contact	50%	Apr-23	57.7%	38.0%	49.2%	75.9%	70.3%	53.3%	54.2%	43.9%	3	7	6	1	2	5	4	4	₩
% of callers allocated the first service offered by DOS	80%	Apr-23	63.2%	69.0%	75.6%	82.6%	78.9%	78.1%	77.6%	66.8%	7	6	5	1	2	3	4	4	♠
% of Cat 3 or 4 ambulance dispositions validated within 30mins	75%	Apr-23	68.8%	59.8%	43.0%	53.8%	57.9%	42.7%	50.5%	38.7%	1	2	6	4	3	7	5	5	•
% of calls initially given an ED disposition that are validated	50%	Apr-23	65.7%	75.2%	43.1%	86.5%	60.8%	26.2%	63.4%	43.4%	3	2	6	1	5	7	4	6	♦
Abandonement Rate for 111 Calls	3%	Apr-23	7.2%	2.0%	18.3%	12.5%	11.4%	17.6%	16.7%	17.0%	2	1	7	4	3	6	5	6	€

New standard for % of callers allocated the first service offered by DOS – 80% down from 85%. New standard for % of Cat 3 or 4 ambulance dispositions validated within 30 mins – 75% up from 50%.

2.2 Urgent Care – Summary Performance – May


Theme	Urgent and Emergency Care metrics	Reporting level	Period	Standard	Latest	Previous	Variance	Change	19/20	Variance	Change	Better is
	Mean 999 call answering time (seconds)	SWASFT	May-23	5	7	2	5		6	1		▼
	Category 2 Response time - Mean (minutes)	BNSSG ICB	May-23	30	28	23	5		26	2		▼
Pre-	Category 2 Response time – 90th centile (minutes)	BNSSG ICB	May-23	40	60	49	11		57	3		▼
hospital	Percentage of conveyances to ED by 999 ambulances	BNSSG ICB	May-23	N/A	46.9%	48.1%	-1.3%		49.6%	-2.8%		▼
	Percentage of NHS 111 calls assessed by a clinicial or clinical advisor	BNSSG ICB	Apr-23	50%	53.3%	49.3%	4.1%		64.3%	-10.9%		
	Percentage of NHS 111 Calls Abandoned	BNSSG ICB	Apr-23	3%	15.9%	10.8%	5.1%		8.4%	7.5%		▼
	Percentage of Ambulance Handovers within 15 minutes	BNSSG Trusts	May-23	65%	26.9%	30.9%	-4.0%	•	68.2%	-41.3%		
	Ambulance Handovers - Average Time Lost per day >15 mins (Hours)	BNSSG Trusts	May-23	N/A	105	59	46		10	95		▼
		NBT	May-23	N/A	75.5%	80.3%	-4.8%		69.2%	6.2%		
A&E	Time to Initial Assessment – percentage of patients assessed within 15 minutes of arival at A&E	BRI	May-23	N/A	65.6%	67.2%	-1.7%		56.0%	9.6%		
AαE		Weston	May-23	N/A	41.3%	48.5%	-7.2%		6.9%	34.4%		
	verage (mean) time in Department –	NBT	May-23	N/A	3:45	3:09	0:35		3:24	3:24		▼
	Average (mean) time in Department – non-admitted patients (hh:mm)	BRI	May-23	N/A	4:46	4:07	0:38		3:42	1:03		▼
	····· ································	Weston	May-23	N/A	3:34	3:33	-0:01		4:00	-0:26		▼
		NBT	May-23	N/A	6:55	5:30	1:24		5:10	1:44		▼
Hospital	Hospital Average (mean) time in Department – admitted patients (hh:mm)	BRI	May-23	N/A	7:22	5:59	1:22		5:16	2:05		▼
		Weston	May-23	N/A	16:30	11:31	4:58		5:28	11:01		▼
		NBT	May-23	2%	3.2%	1.4%	1.9%		0.0%	3.2%		▼
	Percentage of patients spending more than 12 hours from Arrival in A&E	BRI	May-23	2%	7.4%	4.3%	3.1%		1.3%	6.1%		▼
		Weston	May-23	2%	10.9%	11.2%	-0.4%		3.8%	7.1%		▼
		BNSSG Trusts	May-23	0	474	326	148		4	470		▼
Whole System	Number of patients spending more than 12 hours in A&E from a Decision To Admit	NBT	May-23	0	39	2	37		0	39		▼
		UHBW	May-23	0	435	324	111		4	431		▼
		BNSSG Trusts	May-23	76%	68.5%	73.9%	-5.4%		77.7%	-9.2%		
	Percentage of patients waiting 4 hours or less in A&E	NBT	May-23	76%	70.7%	80.2%	-9.5%		76.2%	-5.5%		
		UHBW	May-23	76%	67.5%	70.7%	-3.2%	▼	78.5%	-11.0%		

• Variance between latest month and previous month or latest month and same period in 19/20.

• Change: Is the latest month better (Green Icon) or worse (Red icon) when compare to the previous month or same period in 19/20.

• RAG colours are based on comparison to national standards: **GREEN** = Achieved, **RED** = not achieved

2.2 Urgent Care – Care Homes Occupancy Report



2.3 Planned Care – Drivers and Priority Actions

	Top Improvement Drivers: June 2023	Priority actions: June-July 2023
RTT	 National requirements to clear all remaining >78 week waiters and progress 23/24 trajectories for reducing 65+ww by year end. Noting impacts will be showing in performance as a result of industrial action to date (inc. lost opportunity through reduced booking, cancellations, and displaced activity) and bank holiday days lost. Forward look for elective delivery 	 Weekly scrutiny and detailed returns to Region/National team on 78ww breaches/breach risks continues. System focus shifting to 65+ww cohort; Utilising national DMAS and Region NHSE support to try and secure mutual aid for complex cases; Working closely with the Independent Sector, to manage long waiting cohorts in the same robust way as the Trusts, and working with the IS to establish arrangements to support for some of the systems challenged areas – e.g. skin, colorectal; Continuation of recovery action plans established in 22/23, which include additional lists, weekend work and utilisation of additional capacity through insourcing and outsourcing arrangements; Validation activity continues in both Trusts and both are engaged in a Regional pilot with the CSU –focussing on RTT pathways; BNSSG Elective Centre business case progressing. FBC stage underway; Short stay ortho pathway to be trialled across both Trusts; Options appraisal for transformation of skin pathways to be completed.
Diagnostics	85% of people waiting <6 weeks for their test by 31/03/24.	 Implementation of recovery action plans continues. 23/24 plans achieve the regional ambitions in totality (across all core modalities) although it is recognised that Endoscopy remains a significant challenge across the system. Focussed action plans are in implementation at both Trusts for endoscopy and include additional activity, utilisation and productivity improvement focus and the continued utilisation of insourcing and outsourcing capacity. Histopathology performance improvement being cascaded from the National team, BNSSG will map current position and improvement opportunities. Progress estate works enabled through the Endoscopy Capital funding at the BRI site to regain JAG accreditation; The system is working to conclude the CDC contractual negotiations; The system is working with SWETA and NHSE SW to look at novel ways to develop and expedite training for clinical endoscopists and develop a sustainable broader endoscopy workforce across nursing and administration roles.
Outpatients	 5. Reducing, validating and prioritising patients on outpatient waiting lists 6. Increasing availability and utilisation of advice and guidance. 	 5. Validation activity continues in both Trusts. Both Trusts will engage with the national drive on Outpatient productivity – initial meetings with NHSE have taken place and opportunities identified are being further explored. Initial priorities focus on outpatient productivity and the 65 and 52 week milestones set nationally. PIFU utilised where appropriate and roll out continues. 6. Work continues on A&G, including standardising processes to ensure consistent provision of A&G across all major specialties via eRS; monthly reporting now established and longer response rates escalated via EROG for investigation/action.
Cancer	 7. Backlog position recovery (63+day recovery metric) 8. FDS improvement 9. Pathways of challenge – (inc. focus on capacity/demand modelling, workforce, access to Diagnostics, referral management, space) 	 7. It is recognised that Industrial Action continues to impact cancer services which will continue to impact the 63+ day position and the system is closely monitoring this – it is expected to impact performance in the short term. 8. The system is committed to focussing on improvements in FDS performance. 23/24 plans meet the national ambitions for this metric – June/July continues to prioritise the implementation of plans, recognising the impacts of Industrial Action on lost activity. 9. Skin pathway - Trusts are implementing recovery plans at speciality level and as a system a group has been established to focus on skin pathway improvement – first phase to improve demand management through high quality images at the referral step of the pathway. Gynae pathway - investment in hysteroscopy continues. GI pathways - implementation of FIT changes bedding in and improvements will be made through extra capacity secured.

2.3 Planned Care – Summary Performance – April

BNSSG Population Level

RTT 18 week Incomplete	Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change
Total Waiting List	99,101	85,444	13,657		50,061	49,040	
No. >18 weeks	40,188	30,899	9,289		5,726	34,462	
No.>52 weeks	6,022	4,124	1,898		18	6,004	
No.>65 weeks	1,409	973	436		N/A	N/A	N/A
No. >78 weeks	122	88	34		N/A	N/A	N/A
No. >104 weeks	7	6	1		N/A	N/A	N/A
52ww as % of WL	6.1%	4.8%	1.3%		0.0%	6.0%	
% Performance	59.45%	63.84%	-4.4%	•	74.47%	-15.0%	•

NBT Total Provider

574

554

108

44

-4

2

0.2%

-0.7%

Apr-23 Mar-23 Variance

47,287

17.319

2.576

547

69

7

5.4%

63.37%

47,861

17.873

2.684

591

65

9 5.6%

62.66%

UHBW Total Provider

Change	e Apr-19	Variance	Change	Apr-23	Mar-23	Variance	Chang
	27,995	19,866		66,543	66,379	164	
	4,150	13,723		31,501	30,899	602	
	19	2,665		5,472	5,383	89	
	N/A	N/A	N/A	1,549	1,533	16	
	N/A	N/A	N/A	182	165	17	
	N/A	N/A	N/A	0	1	-1	
	0.1%	5.5%		8.2%	8.1%	0.1%	
	71.82%	-9.2%		52.66%	53.45%	-0.8%	

Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change
66,543	66,379	164		34,290	32,253	
31,501	30,899	602		3,652	27,849	
5,472	5,383	89		14	5,458	
1,549	1,533	16		N/A	N/A	N/A
182	165	17		N/A	N/A	N/A
0	1	-1		N/A	N/A	N/A
8.2%	8.1%	0.1%		0.0%	8.2%	
52.66%	53.45%	-0.8%		70.58%	-17.9%	

Diagnostics	Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change	Apr-23	Mar-23	Variance	Change
Total Waiting List	27,783	29,335	-1,552		21,311	6,472		11,878	12,415	-537	
No.>6 weeks	6,424	6,152	272		839	5,585		2,072	1,990	82	
No. >13 weeks	1,789	2,186	-397		37	1,752		740	939	-199	
% Performance	23.12%	20.97%	2.2%		3.94%	19.2%		17.44%	16.03%	1.4%	

Cancer	Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change
2 week waits	42.85%	59.81%	-17.0%	•	89.52%	-46.7%	•
2ww breast	50.00%	69.63%	-19.6%		89.74%	-39.7%	
28 day FDS (All Routes)	66.12%	74.50%	-8.4%	•	N/A	N/A	N/A
31 day first treatment	89.18%	92.86%	-3.7%	▼	95.89%	-6.7%	•
31 day - Surgery	85.87%	87.50%	-1.6%	▼	89.38%	-3.5%	•
31 day - Drugs	98.58%	99.37%	-0.8%	▼	98.52%	0.1%	
31 day - Radiotherapy	98.62%	99.42%	-0.8%	▼	96.02%	2.6%	
62 day	61.14%	63.90%	-2.8%	•	86.55%	-25.4%	▼
62 day - Screening	55.56%	75.76%	-20.2%	•	92.31%	-36.8%	

Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Chang
41.63%	56.84%	-15.2%		84.89%	-43.3%	
42.86%	67.16%	-24.3%		93.37%	-50.5%	
68.05%	78.17%	-10.1%		N/A	N/A	N/A
79.58%	91.04%	-11.5%		93.07%	-13.5%	▼
72.97%	79.79%	-6.8%		80.00%	-7.0%	▼
83.33%	100.00%	-16.7%		100.00%	-16.7%	
N/A	N/A	N/A	N/A	N/A	N/A	N/A
55.29%	61.62%	-6.3%		83.84%	-28.5%	▼
57.14%	73.58%	-16.4%		93.33%	-36.2%	▼

Apr-19

10,157

434

15

4.25%

Variance Change

1.721

1.638

725

13.2%

Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change
16,589	17,333	-744		11,672	4,917	
4,671	4,450	221		475	4,196	
1,310	1,484	-174		23	1,287	
28.16%	25.67%	2.5%		4.09%	24.1%	

Apr-23	Mar-23	Variance	Change	Apr-19	Variance	Change
41.36%	59.02%	-17.7%		93.35%	-52.0%	
N/A	N/A	N/A	N/A	N/A	N/A	N/A
60.03%	65.42%	-5.4%		N/A	N/A	N/A
93.14%	92.92%	0.2%		95.38%	-2.2%	
88.68%	83.61%	5.1%		95.92%	-7.2%	
98.67%	98.72%	-0.1%		100.00%	-1.3%	
99.37%	99.50%	-0.1%		96.45%	2.9%	
68.03%	67.42%	0.6%		86.34%	-18.3%	
25.00%	85.71%	-60.7%		71.43%	-46.4%	•

Key to Tables

- Latest month = **April** Previous month = **March** 19/20 = April 2019 (pre-covid comparison)
- Variance: between latest month and previous month or latest month and same period in 19/20
- Change: Is the latest month better (Green Icon) or worse (Red icon) when compare to the previous month or the same period in 19/20.
- RAG colours are based on comparison to national standards: GREEN = Achieved, RED = not achieved


2.4 Mental Health – Summary Performance

Mental Health, Learning Disabilities & Autism	Period	Standard	Latest	Previous	Variance	Change	19/20	Variance	Change
Dementia Diagnosis Rate	Apr-23	66.7%	66.5%	66.4%	0.1%		66.4%	0.1%	
EIP - 2ww Referral	Dec-22	60%	62.5%	75.0%	-12.5%	▼	75.0%	-12.5%	
IAPT Roll out (rolling 3 months)	Mar-23	6.25%	4.53%	4.20%	0.33%		3.8%	0.7%	
IAPT Recovery Rate	Mar-23	50%	52.5%	52.7%	-0.2%	▼	39.7%	12.8%	
IAPT Waiting Times - 6 weeks	Mar-23	75%	97.8%	97.1%	0.7%		82.3%	15.5%	
IAPT Waiting Times - 18 weeks	Mar-23	95%	100.0%	100.0%	0.0%	•	99.0%	1.0%	
CYPMH Access Rate - 2 contacts (12m Rolling)	Mar-23	34%	32.4%	32.3%	0.1%		27.0%	5.4%	
CYP with Eating Disorders - routine cases within 4 weeks	Q4 22-23	95.0%	95.5%	96.0%	-0.5%	▼	89.8%	5.7%	
CYP with Eating Disorders - urgent cases within 1 week	Q4 22-23	95.0%	95.2%	96.0%	-0.8%	▼	55.2%	40.1%	
SMI Annual Health Checks (12 month rolling)	Q4 22-23	60.0%	62.2%	50.9%	11.3%		18.2%	44.1%	
Total Innapropriate Out of Area Placements (Bed Days)	Mar-23	N/A	80	90	-10		1172	-1092	•
Percentage of Women Accessing Perinatal MH Services	Mar-23	8.6%	7.3%	7.2%	0.1%		N/A	N/A	N/A
Reliance on inpatient care for people with a LD and/or autism - Adults in CCG beds	May-23	6	11	10	1		N/A	N/A	N/A
Reliance on inpatient care for people with a LD and/or autism - Adults in NHSE beds	May-23	12	19	19	0		N/A	N/A	N/A
LD Annual Health Checks delivered by GPs aged 14+ (YTD)	Apr-23	3825	130	0	130		N/A	N/A	N/A
AWP Delayed Transfers of Care	May-23	3.5%	24.0%	23.1%	0.9%		5.2%	18.8%	
AWP Early Intervention	May-23	60%	68.1%	41.1%	27.0%		80.0%	-11.9%	•
AWP 4 week wait referral to assessment	May-23	95%	92.19%	93.70%	-1.5%	•	96.00%	-3.8%	▼

Key to Table

- Latest = Latest month / quarter Previous = Previous month / quarter 19/20 = same month or period in 19/20 (pre-covid comparison), where available
- Standard = National Standard, where available
- Variance: between latest period and previous period or latest period and same period in 19/20
- Change: Is the latest period better (Green Icon) or worse (Red icon) when compare to the previous period or same period in 19/20.
- RAG colours are based on comparison to national standards: **GREEN** = Achieved, **RED** = not achieved

2.5 Sirona – Adults Community Services – % in 18 weeks – 2023/24 YTD



Data source: Sirona Adults Contractual Reporting Dashboard 2022/23 – Percentage of patients seen within 18 weeks compared to 95%


Target

95%

100%

Target

2.6 Children – CYP ED Overview BNSSG Trusts - April



Data source: NHSEI Children and Young People Emergency Department Dashboard (Ages 0-19)

3.1 BNSSG ICB Scorecard

Theme	Indicator	Standard	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23
	A&E 4hr Waits - BNSSG Footprint	95%	65.76%	72.74%	69.21%	66.32%	61.78%	66.15%	64.95%	65.00%	63.10%	73.80%	74.50%	76.46%	79.52%	74.93%
Urgent Care	A&E 4hr Waits - BNSSG Trusts	95%	59.46%	65.46%	61.80%	57.10%	61.78%	60.07%	58.87%	56.72%	54.12%	66.27%	67.75%	70.70%	73.92%	68.54%
Cale	>12hr DTA breaches in A&E - BNSSG Trusts	0	1169	755	873	1182	815	978	1423	1296	2003	1318	436	680	326	474
	RTT Incomplete - 18 Weeks Waits	92%	65.75%	65.76%	66.17%	65.71%	65.75%	65.54%	66.25%	64.72%	62.55%	64.12%	64.26%	63.84%	59.45%	
	RTT Incomplete - Total Waiting List Size		75,720	76,803	80,749	85,720	87,320	86,771	87,481	80,290	85,246	86,001	83,947	85,444	99,101	
	RTT Incomplete - 52 Week Waits		4052	4164	4764	5134	5376	5302	5386	4761	5345	4961	4182	4124	6,022	
Planned	RTT Incomplete - % of WL > 52 Weeks		5.35%	5.42%	5.90%	5.99%	6.16%	6.11%	6.16%	5.93%	6.27%	5.77%	4.98%	4.83%	6.08%	
Care	Diagnostic - 6 Week Waits	1%	41.09%	38.14%	38.46%	38.36%	41.30%	40.46%	36.03%	34.05%	35.13%	32.18%	24.95%	20.97%	23.12%	
	Diagnostic - Total Waiting List Size		32,109	31,592	31,976	31,991	31,480	33,279	33,598	32,634	30,471	29,469	28,816	29,335	27,783	
	Diagnostic - Number waiting > 6 Weeks		13,193	12,049	12,298	12,273	13,000	13,464	12,105	11,111	10,705	9,484	7,190	6,152	6,424	
	Diagnostic - Number waiting > 13 Weeks		7,543	7,539	7,597	7,099	7,067	7,503	7,009	6,033	5,456	4,267	3,100	2,186	1,789	
	Cancer 2 Week Wait - All	93%	61.38%	57.06%	48.91%	44.15%	44.78%	39.17%	39.58%	47.13%	53.08%	56.34%	65.15%	59.81%	42.85%	
	Cancer 2 Week Wait - Breast symptoms	93%	21.35%	52.86%	22.83%	35.56%	4.88%	14.55%	20.83%	73.21%	90.74%	87.88%	88.04%	69.63%	50.00%	
	Cancer 28 day faster diagnosis standard (All Routes)	75%	67.96%	72.62%	69.30%	61.04%	53.13%	41.55%	45.75%	52.52%	53.60%	61.31%	72.01%	74.50%	66.12%	
	Cancer 31 Day first treatment	96%	86.60%	89.02%	91.31%	93.53%	92.83%	89.69%	93.44%	91.74%	93.39%	86.98%	91.81%	92.86%	89.18%	
Cancer	Cancer 31 day subsequent treatments - surgery	94%	71.00%	70.91%	68.48%	70.11%	67.02%	64.81%	85.29%	78.23%	83.33%	59.32%	91.94%	87.50%	85.87%	
	Cancer 31 day subsequent treatments - anti-cancer drugs	98%	97.66%	100.00%	95.83%	97.76%	100.00%	100.00%	100.00%	100.00%	100.00%	91.40%	98.81%	99.37%	98.58%	
	Cancer 31 day subsequent treatments - radiotherapy	94%	100.00%	100.00%	98.87%	100.00%	100.00%	98.61%	98.64%	98.84%	100.00%	99.40%	99.34%	99.42%	98.62%	
	Cancer 62 day referral to first treatment - GP referral	85%	61.21%	57.96%	53.53%	56.90%	56.00%	59.56%	50.79%	51.13%	51.22%	43.10%	54.33%	63.90%	61.14%	
	Cancer 62 day referral to first treatment - NHS Screening	90%	55.56%	82.14%	43.48%	62.16%	69.70%	54.55%	58.82%	54.17%	48.00%	47.50%	71.43%	75.76%	55.56%	
	Total Number of C.diff Cases	308	23	20	27	27	26	26	21	26	20	14	10		26	
	Total Number of MRSA Cases Reported	0	4	2	1	1	2	5	1	4	1	2	3		1	
Quality	Total number of Never Events	0	0	0	0	0	1	1	0	2	2	1	0	0	0	
	Eliminating Mixed Sex Accommodation (BNSSG CCG)	0	1	0	2	1	1	1	0	1	3	3	0	5	10	
	Eliminating Mixed Sex Accommodation (BNSSG Trusts)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dementia Diagnosis Rate - People 65+	66.7%	65.80%	65.88%	65.72%	65.92%	65.79%	66.09%	66.54%	67.19%	66.66%	66.60%	66.40%	66.40%	66.50%	
	EIP - 2ww Referral	60%	76.92%	70.00%	66.67%	58.33%	69.23%	72.73%	77.78%	75.00%	62.50%	N/A	N/A	N/A		
	IAPT Roll out (rolling 3 months)	6.25%	4.44%	4.66%	4.35%	4.24%	4.00%	3.92%	3.91%	4.00%	3.92%	4.32%	4.20%	4.53%		
	IAPT Recovery Rate	50%	50.60%	51.81%	52.15%	51.71%	50.46%	46.15%	48.17%	52.60%	55.15%	50.63%	52.73%	52.54%		
Mental	IAPT Waiting Times - 6 weeks	75%	93.60%	92.42%	95.26%	95.69%	96.41%	95.68%	98.80%	96.61%	97.16%	96.97%	97.09%	97.81%		
Health	IAPT Waiting Times - 18 weeks	95%	100.00%	99.49%	100.00%	99.52%	99.55%	99.46%	100.00%	99.44%	99.29%	99.39%	100.00%	100.00%		
	CYPMH Access Rate 2+ contacts (rolling 12m)	34%	28.08%	30.54%	31.47%	31.97%	32.47%	31.82%	32.20%	32.61%	32.32%	32.38%	32.29%	32.44%		
	CYP with ED - routine cases within 4 weeks (quarterly)	95%		91.35%			95.31%			95.95%			95.95%			
	CYP with ED - urgent cases within 1 week (quarterly)	95%		91.67%			95.00%			96.00%			96.00%			
	SMI Annual Health Checks (quarterly)	60%		56.81%			55.40%			50.94%			62.24%			
	Out of Area Placements (Bed Days)		450	470	455	330	265	175	65	120	120	90	90	80		

3.2 Provider Scorecard – NBT

Theme	Indicator	Standard	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23
11	A&E 4hr Waits - Trust	95%	55.54%	72.71%	59.32%	50.99%	60.83%	56.43%	57.47%	57.87%	55.61%	71.94%	79.69%	78.35%	80.16%	70.65%
Urgent Care	A&E 4hr Waits - Footprint	95%	61.71%	77.70%	66.62%	60.85%	60.83%	62.29%	63.12%	65.67%	63.82%	77.64%	83.37%	82.07%	83.86%	76.06%
	>12hr DTA breaches in A&E	0	360	176	297	304	57	261	482	433	786	312	9	135	2	39
	RTT Incomplete - 18 Weeks Waits	1%	64.23%	62.62%	64.80%	65.78%	65.82%	66.30%	66.31%	65.58%	62.05%	63.87%	63.87%	63.37%	62.66%	
	RTT Incomplete - Total Waiting List Size	Op Plan	39,819	40,634	42,326	46,991	48,766	49,025	48,871	47,418	46,523	46,266	46,327	47,287	47,861	
	RTT Incomplete - 52 Week Waits	Op Plan	2,454	2,424	2,675	2,914	3,131	3,087	3,062	2,980	2,984	2,742	2,556	2,576	2,684	
Planned	RTT Incomplete - % of WL > 52 Weeks		6.16%	5.97%	6.32%	6.20%	6.42%	6.30%	6.27%	6.28%	6.41%	5.93%	5.52%	5.45%	5.61%	
Care	Diagnostic - 6 Week Waits	1%	43.61%	40.13%	41.00%	42.75%	48.09%	48.27%	39.36%	38.62%	38.56%	32.21%	22.45%	16.03%	17.44%	
	Diagnostic - Total Waiting List Size		17,114	17,166	17,504	17,124	16,928	16,690	17,286	16,740	14,988	13,437	12,679	12,415	11,878	
	Diagnostic - Number waiting > 6 Weeks		7,464	6,889	7,177	7,321	8,141	8,057	6,803	6,465	5,779	4,328	2,847	1,990	2,072	
	Diagnostic - Number waiting > 13 Weeks		4,664	4,780	4,897	4,718	4,844	4,971	4,627	4,204	3,663	2,459	1,497	939	740	
	Cancer 2 Week Wait - All	93%	57.66%	46.16%	39.21%	40.99%	40.18%	35.85%	30.86%	47.53%	56.62%	55.01%	63.52%	56.84%	41.63%	
	Cancer 2 Week Wait - Breast symptoms	93%	14.94%	46.03%	18.95%	21.05%	2.50%	6.12%	11.94%	63.27%	97.83%	90.16%	87.50%	67.16%	42.86%	
	Cancer 28 day faster diagnosis standard (All Routes)	75%	66.82%	72.83%	70.87%	58.29%	48.83%	35.18%	42.88%	55.74%	55.48%	62.66%	77.41%	78.17%	68.05%	
Cancer	Cancer 31 Day first treatment	96%	81.82%	83.77%	85.53%	91.20%	87.36%	87.76%	90.39%	86.49%	87.16%	82.41%	89.90%	91.04%	79.58%	
Cancer	Cancer 31 day subsequent treatments - surgery	94%	62.77%	57.29%	51.85%	58.11%	43.84%	50.00%	75.51%	64.35%	73.85%	52.21%	80.73%	79.79%	72.97%	
	Cancer 31 day subsequent treatments - anti-cancer drugs	98%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	93.75%	100.00%	83.33%	
	Cancer 62 day referral to first treatment - GP referral	85%	56.48%	50.15%	48.40%	45.10%	55.59%	58.90%	52.45%	48.86%	49.00%	41.54%	57.82%	61.62%	55.29%	
	Cancer 62 day referral to first treatment - NHS Screening	90%	63.64%	82.14%	51.02%	57.53%	74.24%	62.50%	57.38%	63.83%	51.02%	54.22%	70.00%	73.58%	57.14%	
	Total Number of C.diff Cases (HOHA + COHA)		7	7	7	7	5	6	6	6	6	4	2		4	
	Total Number of MRSA Cases Reported	0	4	1	1	0	0	0	0	0	0	0	0	2	0	
	Total Number of E.Coli Cases		7	5	7	4	6	5	6	8	4	9	6		8	
Quality	Number of Klebsiella cases		2	3	4	2	1	4	2	2	2	1	2		1	
	Number of Pseudomonas Aeruginosa cases		2	1	0	1	2	1	0	0	4	2	1		1	
	Eliminating Mixed Sex Accommodation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of Never Events	0	0	0	0	0	0	0	0	2	1	1	0	0	0	
	VTE assessment on admission to hospital	95%	94.75%	94.68%	94.68%	92.23%	91.68%	91.76%	93.01%	94.08%	93.91%	94.23%	94.15%	92.97%		

3.3 Provider Scorecard – UHBW

Theme	Indicator	Standard	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23
Liverent	A&E 4hr Waits - Trust	95%	61.51%	61.69%	63.04%	60.15%	62.31%	62.01%	59.59%	56.17%	53.41%	63.45%	61.90%	66.88%	70.67%	67.48%
Urgent Care	A&E 4hr Waits - Footprint	95%	67.81%	70.28%	70.47%	68.96%	62.31%	68.14%	65.86%	64.68%	62.77%	71.95%	70.29%	73.74%	77.37%	74.38%
Garo	>12hr DTA breaches in A&E	0	809	579	576	878	758	717	941	863	1217	1006	427	545	324	435
	RTT Incomplete - 18 Weeks Waits	1%	58.65%	58.32%	58.76%	56.37%	55.56%	54.35%	55.33%	55.19%	54.36%	55.62%	54.25%	53.45%	52.66%	
	RTT Incomplete - Total Waiting List Size	Op Plan	57,019	57,940	60,404	60,738	62,010	61,870	62,462	63,041	64,359	64,847	64,929	66,379	66,543	
	RTT Incomplete - 52 Week Waits	Op Plan	4,362	4,654	5,298	5,591	5,970	6,141	5,989	5,888	6,011	5,498	5,371	5,383	5,472	
Planned	RTT Incomplete - % of WL > 52 Weeks		7.65%	8.03%	8.77%	9.21%	9.63%	9.93%	9.59%	9.34%	9.34%	8.48%	8.27%	8.11%	8.22%	
Care	Diagnostic - 6 Week Waits	1%	42.11%	39.90%	38.78%	36.50%	37.79%	35.54%	34.66%	31.49%	34.21%	34.12%	27.88%	25.67%	28.16%	
	Diagnostic - Total Waiting List Size		16,521	15,819	16,042	16,426	15,387	17,577	16,952	16,692	16,339	16,731	17,080	17,333	16,589	
	Diagnostic - Number waiting > 6 Weeks		6,957	6,311	6,221	5,996	5,815	6,246	5,875	5,256	5,589	5,709	4,762	4,450	4,671	
	Diagnostic - Number waiting > 13 Weeks		3,799	3,697	3,616	3,245	2,968	3,294	3,062	2,317	2,307	2,190	1,933	1,484	1,310	
	Cancer 2 Week Wait - All	93%	63.02%	67.99%	57.22%	44.62%	45.18%	41.14%	49.06%	41.57%	41.93%	50.26%	60.49%	59.02%	41.36%	
	Cancer 28 day faster diagnosis standard (All Routes)	75%	72.02%	73.19%	67.40%	64.56%	57.28%	50.54%	46.76%	42.78%	45.98%	53.23%	58.46%	65.42%	60.03%	
	Cancer 31 Day first treatment	96%	89.58%	90.61%	92.88%	93.92%	93.92%	91.01%	94.61%	93.36%	98.33%	88.36%	92.83%	92.92%	93.14%	
Cancer	Cancer 31 day subsequent treatments - surgery	94%	83.33%	76.27%	80.00%	88.89%	85.94%	87.69%	84.21%	88.71%	87.23%	72.34%	93.55%	83.61%	88.68%	
Carloon	Cancer 31 day subsequent treatments - anti-cancer drugs	98%	97.67%	100.00%	94.77%	98.53%	100.00%	100.00%	100.00%	99.44%	100.00%	90.21%	99.39%	98.72%	98.67%	
	Cancer 31 day subsequent treatments - radiotherapy	94%	99.38%	100.00%	99.48%	99.38%	100.00%	99.37%	98.73%	98.99%	99.29%	99.47%	99.42%	99.50%	99.37%	
	Cancer 62 day referral to first treatment - GP referral	85%	67.81%	70.95%	61.83%	69.42%	52.16%	64.85%	47.95%	46.37%	53.98%	42.91%	44.39%	67.42%	68.03%	
	Cancer 62 day referral to first treatment - NHS Screening	90%	0.00%	33.33%	25.00%	50.00%	50.00%	50.00%	85.71%	44.44%	75.00%	40.00%	66.67%	85.71%	25.00%	
	Total Number of C.diff Cases (HOHA + COHA)	89	6	8	12	13	7	9	6	13	7	5	8	6	12	
	Total Number of MRSA Cases Reported	0	0	0	0	0	0	1	0	1	1	2	1	1	1	
	Total Number of E.Coli Cases	119	15	13	6	8	7	11	13	9	5	5	6	6	9	
	Number of Klebsiella cases		3	4	5	6	9	5	5	10	3	3	1	1	2	
Quality	Number of Pseudomonas Aeruginosa cases		1	2	1	2	4	5	1	0	0	3	1	1	2	
Quality	Eliminating Mixed Sex Accommodation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of Never Events	0	0	0	0	0	1	1	0	0	1	0	0	0	0	
	Rate of slips, trips and falls per 1,000 bed days	4.8	5.55	4.79	4.11	3.27	6.63	4.49	5.86	5.34	4.71	5.11	5.23	5.14	5.29	
	No. of Pressure Ulcers grade 2, 3 & 4 per 1,000 bed days	0.4	0.248	0.089	0.093	0.089	0.118	0.061	0.23	0.18	0.088	0.086	0.1	0.147	0.032	
	VTE assessment on admission to hospital (Bristol)	95%	81.3%	81.9%	82.4%	82.1%	83.7%	83.5%	84.0%	84.9%	81.3%	85.3%	84.50%	83.50%	82.00% 14	

3.4 Non-Acute Provider Scorecard

Provider	Indicator (BNSSG level - except ambulance handovers)	Standard	Apr-22	May-22	Jun-22	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23
	Category 1 - Average Duration (hr:min:sec)	0:07:00	0:09:54	0:08:48	0:09:24	0:10:12	0:09:30	0:09:06	0:09:42	0:08:48	0:11:30	0:08:18	0:07:54	0:08:00	0:07:36	0:07:54
	Category 1 - 90th Percentile Duration (hr:min:sec)	0:14:00	0:17:24	0:15:24	0:15:54	0:17:42	0:16:36	0:15:42	0:16:36	0:15:18	0:19:12	0:14:36	0:14:12	0:14:00	0:13:30	0:13:54
	Category 2 - Average Duration (hr:min:sec)	0:30:00	1:16:30	0:40:42	0:57:12	1:09:54	0:42:00	0:45:12	1:06:00	0:50:24	2:49:24	0:30:06	0:27:54	0:29:06	0:23:06	0:28:06
	Category 2 - 90th Percentile Duration (hr:min:sec)	0:40:00	3:06:18	1:28:54	2:17:48	2:47:00	1:29:18	1:43:12	2:35:54	1:55:30	7:25:12	1:05:24	1:00:30	1:02:48	0:48:30	1:00:06
	Category 3 - 90th Percentile Duration (hr:min:sec)	2:00:00	10:55:12	6:28:06	8:49:30	9:14:18	5:32:06	7:54:54	11:01:30	8:51:24	16:56:54	2:58:00	3:40:18	4:20:12	3:19:18	4:18:00
	Category 4 - 90th Percentile Duration (hr:min:sec)	3:00:00	13:58:36	6:02:18	5:44:00	10:35:54	7:20:18	8:39:54	2:40:06	14:35:00	14:35:36	4:21:54	3:27:18	6:52:12	4:34:24	7:50:36
	Ambulance Handovers - % within 15 minutes at NBT	65%	16.8%	21.0%	16.8%	13.5%	18.2%	17.6%	11.9%	13.1%	9.6%	19.5%	26.7%	23.0%	34.9%	29.2%
SWASFT	Ambulance Handovers - % within 30 minutes at NBT	95%	44.4%	53.9%	45.5%	42.8%	56.2%	51.5%	38.6%	40.3%	29.6%	54.7%	70.9%	67.5%	79.2%	70.7%
	Ambulance Handovers - % within 60 minutes at NBT	100%	66.2%	77.2%	68.0%	67.5%	80.9%	75.9%	62.2%	66.2%	48.8%	78.9%	94.7%	89.1%	96.1%	91.4%
	Ambulance Handovers - % within 15 minutes at BRI	65%	11.6%	13.9%	17.5%	9.7%	12.0%	13.3%	10.3%	11.4%	7.5%	12.1%	11.9%	14.2%	24.5%	18.7%
	Ambulance Handovers - % within 30 minutes at BRI	95%	25.3%	34.7%	42.9%	26.2%	30.7%	36.1%	27.7%	33.7%	17.8%	33.5%	37.1%	44.6%	61.4%	48.0%
	Ambulance Handovers - % within 60 minutes at BRI	100%	44.2%	56.0%	65.2%	48.1%	51.2%	58.4%	49.7%	60.8%	36.1%	58.7%	69.1%	72.8%	87.6%	74.1%
	Ambulance Handovers - % within 15 minutes at WGH	65%	16.9%	25.0%	23.5%	15.0%	19.0%	16.3%	14.2%	12.4%	5.8%	11.0%	19.4%	13.8%	14.7%	16.2%
	Ambulance Handovers - % within 30 minutes at WGH	95%	40.5%	52.4%	55.9%	36.3%	47.5%	46.6%	44.0%	37.1%	23.7%	38.6%	58.9%	52.6%	54.3%	54.7%
	Ambulance Handovers - % within 60 minutes at WGH	100%	58.1%	71.2%	72.7%	56.0%	65.0%	66.2%	65.2%	63.0%	42.4%	59.4%	85.5%	82.9%	83.3%	78.2%
	Average speed to answer calls (in seconds)	20 Sec	318	274	756	713	723	271	453	381	2054	269	181	152	151	
	% of calls abandoned	3%	16.1%	13.5%	30.0%	28.4%	29.2%	14.0%	20.6%	18.0%	43.3%	14.9%	12.2%	10.8%	0.0%	
SevernSide	% Triaged Calls receiving Clinical Contact	50%	50.0%	48.5%	48.4%	48.8%	37.3%	51.5%	52.1%	51.0%	51.9%	50.3%	50.2%	49.3%	53.3%	
IUC	% of callers allocated the first service offered by DOS	80%	70.0%	68.7%	69.3%	70.2%	68.8%	70.1%	68.8%	67.7%	70.9%	73.0%	71.4%	73.4%	78.1%	
	% of Cat 3 or 4 ambulance dispositions validated within 30mins	75%	53.1%	45.8%	38.0%	45.0%	58.5%	66.2%	60.9%	56.3%	38.0%	44.8%	42.4%	33.0%	42.7%	
	% of calls initially given an ED disposition that are validated	50%	24.2%	13.2%	13.8%	13.4%	17.9%	22.5%	23.9%	21.0%	27.0%	24.1%	27.4%	29.8%	26.2%	
	Delayed Transfers of Care	3.5%	10.3%	13.4%	10.6%	12.7%	15.8%	18.4%	20.4%	21.5%	23.9%	23.9%	21.9%	23.6%	23.1%	24.0%
AWP	Early Intervention	60%	76.9%	55.0%	63.1%	81.8%	76.1%	73.3%	81.8%	62.5%	64.2%	28.5%	73.3%	39.1%	41.1%	68.1%
	4 week wait Referral to Assessment	95%	78.9%	76.9%	76.9%	84.3%	82.9%	75.0%	84.2%	83.0%	90.3%	90.5%	97.6%	95.6%	93.7%	92.2%

Please note: Regarding SevernSide IUC data, a cyber-attack on 4th August 2022 caused a major outage on the Adastra system used by many IUC service providers. This had a widespread impact on the IUC service with many providers relying on paper record-keeping from that date onwards during August. Besides impacting service delivery in August, ongoing reporting issues have resulted in missing or under-reported data for some contract areas and caution should be taken when interpreting figures from August to November.

December saw an exceptional increase in calls received by NHS 111, with demand close to that seen in March 2020. Service providers attribute much of the increase to winter pressures, including widespread public concern about Group A Streptococcus infections



BNSSG Outcomes, Performance and Quality Committee

Minutes of the meeting held on Thursday 27th April, 1400-1630, on MS Teams

Minutes

Present		
Ellen Donovan (Chair)	Non-Executive Member for Quality and Performance, BNSSG ICB	ED
Jeff Farrar	Chair, BNSSG ICB	JF
Joanne Medhurst	Chief Medical Officer, BNSSG ICB	JM
Rosi Shepherd	Chief Nursing Officer, BNSSG ICB	RS
Lisa Manson	Director of Performance and Delivery, BNSSG ICB	LM
Colin Bradbury 1400- 1530	Director of Strategy, Partnerships and Population, BNSSG ICB	CB
Jonathan Hayes	Chair GP Collaborative Board	JH
Sarah Weld	Director of Public Health, South Gloucestershire Council	SW
In attendance		
Sarah Jones 1610- 1620	Director of Nursing, AWP	SJ
Dani Sapsford	Head of Performance Improvement	DS
Phil Cooper 1610- 1620	Head of Governance, AWP	PC
Glenda Beard	GP and Clinical Lead Cancer BNSSG ICB	GB
Vicky Marriott	Healthwatch (Representing Sue Geary)	VM
Layla Toomer	Patient Safety Lead Maternity and Neonatology, BNSSG ICB	LT
Jodie Stephens (notes)	Executive PA, BNSSG ICB	TM
Apologies		
Paul May	Non-Executive Director, Sirona	PM
Sue Balcombe	Non-Executive Director, UHBW	SB
Sue Geary	Healthwatch	SG
Denise Moorhouse	Deputy Chief Nursing Officer, BNSSG ICB	DM
Hugh Evans	Executive Director, Adults & Communities, Bristol City Council	HE
Michael Richardson	Deputy Chief Nursing Officer, BNSSG ICB	MR



	Item	Action
1	Welcome and Apologies	
	ED welcome and apologies were noted as above.	
	ED also stated the key aims of the ICB which are the following:	
	 Improve outcomes in population health and healthcare. 	
	 Tackle inequalities in outcomes, experience and access. 	
	Enhance productivity and value for money.	
	Help the NHS support broader social and economic development.	
	ED explained agenda item 6.3 2WW Cancer GP Referral/Consultant is not a deep dive but an opportunity to look at an area of performance in a bit more detail.	
2	Declarations of Interest	
	No new declarations noted.	
3		
	Minutes of March 2023 meeting	
	The following changes were noted and added to March minutes:	
	Agenda Item 4 – Healthwatch Responses Action: LM and RS will take the Healthwatch case studies to Dave Jarrett and Sarah Truelove to follow up and action.	
	ED asked LM to discuss in more detail Dermatology cancer referrals and to update Sirona's 104/78 week wait. The Dermatology update will take place within agenda item 6.3 in today's meeting.	
4	Healthwatch Responses.	
	VM shared with the group feedback from patients as outlined below:	
	 Positive feedback regarding service and after care for family member at Weston General Hospital and 111. GR access to care at Bradley Stoke Surgery 20mins wait on phone to get 	
	 GP access to care at Bradley Stoke Surgery – 30mins wait on phone to get through to GP once they do only can book a phone call but would like to see GP face to face. 	
	 Access to assessment – Patient is currently in dementia nursing home awaiting an assessment from social worker, but patient does not have 	

Shaping better health

	Item	Action
	 dementia. Patient cannot even go outside in gardens because staff not available to escort. Fees will now have to be paid due to the amount of time patient in care home. Mendip Vale Medical Practice- Patient submitted an e-consultation but still not received any response after 3 weeks despite chasing twice. 	
	JH asked VM what happens to the feedback and whether Healthwatch contacts the services and escalates issues. VM explained quarterly reports are produced by Healthwatch and shared with the request for feedback, this is occasionally received. Healthwatch also use the feedback to inform their own work plans and use the themes to identify in depth work, an example being the recent work on ageing well. JH asked VM if there was a quality improvement opportunity for a specific practice or group of patients and how patients directly raise their concerns with the provider. VM explained that Healthwatch would give advice and contact information to the patient but don't make contact on behalf of the patient.	
	ED asked committee members how we benchmark against other areas. RS explained that practices take part in a patient survey every year which is benchmarked with other systems.	
	ED asked how that is used to support quality improvement. LM explained that every practice reports into GPAD and that the information is shared with ICB Primary Care Operational Group which is led by David Jarrett team and reported to ICB Primary Care Committee.	
5	CNO/CMO Update	
	 Emerging Risk Quality Report (highlights and exceptions) BNSSG Commissioning Policy – Update Updates from SQG & HCPE Minutes from SQG & HCPE for information RS briefed committee members about the planned RCN industrial action which is due to take place from 20.00 Sunday 30th April to 20.00 Tuesday. The risk profile is increasing with each round of industrial action and with this action taking place over the weekend and bank holiday where there is less infrastructure to lean into compared to a normal working day. The feedback is that some other parts of the country have a bigher BCN membership and so maybe more affected than both the SW and BNSSG. 	
	higher RCN membership and so maybe more affected than both the SW and BNSSG. Specific areas of concern include Bristol Childrens Hospital, especially the emergency department and high dependency unit caring for children with burns and neurological conditions. There are also concerns about adult critical care areas and Emergency Departments where there will be a significant shortfall in registered nurses creating a	

Item	Action
very risk profile. There is an escalation process in place which had been agreed between NHSE and the RCN. Trusts are being asked to complete any requests for Critical Safety Mitigations which are to be signed off at trust level, then RS and then region. Legal action is being heard in the High Court this afternoon and anticipate feedback by Friday 28 th April.	
JM highlighted the BNSSG Commissioning Policy paper which outlines the policies recommended for adoption or removal following the Clinical Policy Review Groups (CPRG) in January and May 2022. These policies were not approved in 2022 due to the transition from Clinical Commissioning Group (CCG) to Integrated Care Board (ICB). The CCG Governance arrangements were stood down in June 2022 and the new Governance arrangements post-CPRG meeting were not agreed until January 2023. The Commissioning Policy Development (CPD) team, Clinical Lead and Policy Officers have reviewed the 14 policies recommended for adoption and three for removal. Following risk stratification JM approved the proposed changes as deemed low risk reputationally and within the financial limits laid out in the decision making framework. Changes to the policies were approved at a meeting between the CPD team and JM in April 2023. JM explained that an overview of the new governance arrangements can be found in appendix one within the paper. ED asked JM to clarify that JM is not asking this committee to scrutinise, challenge or to provide any assurance but to note the process which has taken place, JM confirmed to committee members that was correct.	
JF asked JM to confirm if there is a written criteria for escalation to committee or ICB Board using autism as an example that has had a lot of press attention. He asked at what point does JM decides between making a decision as Chief Medical Officer or escalating to committee or ICB Board for assurance. JM stated that this would be based on the risk and decision-making framework signed off at Board and if JM was in any doubt would agree with JF to bring to ICB Board.	
Life expectancy has deteriorated for the first time in over 50 years during Covid, this had started to improve but now appears to be stalling. JM will report back to committee both the outcome of the analytic work and the system approach to addressing this issue.	
SW referred to Action 76 on the committee action log which was assigned to her in relation to BNSSG excess mortality rates. SW proposed that the action be assigned to JM but that SW would support along with Director of Public Health colleagues. JM agreed. SW asked JM if the analytic data which was produced and at regional meeting yesterday could be shared with SW and ED asked for the data to be included in the report which JM is due to bring to OPQ Committee.	
JM updated members that she had attended a Women's Health conference covering all aspects of women's health e.g., reproductive, menopause, gynaecology, and	

	Item	Action
	urology. JM and system Directors of Public Health will scope a piece of work aimed at addressing inequalities in relation to women's health.	
	RS highlighted to committee of two other emerging concerns access to interpretation and translation services and safeguarding issues with the growing numbers of refugees and asylum seekers in BNSSG. The safeguarding issues had originally been observed in South Gloucestershire but are now being experienced in Bristol and North Somerset. Dave Jarrett will be leading a systemwide refugee and asylum- seeking group and MR will join that from a safeguarding perspective.	
	RS also updated that Health Education England have visited Weston General Hospital and have reported good progress and now are hoping to return some medical trainees to Weston General Hospital in 2023.	
	ED praised the excellent news regarding Weston General Hospital which has been a collaborative approach from the system and should be highlighted to ICB Board and Shane Devlin including lessons learned.	
	ACTION 88: JM to share excess mortality analytic data which was circulated at Regional CMO meeting with SW and JM to include that data within the update at July OPQ Committee.	
6.1	BNSSG ICB Strategy – Update CB updated committee on the developing ICS Strategy. The current draft has been discussed in detail with the ICB Executive recently focussing on the strategic direction of the system and how the Health and Care Improvement Groups will take oversight of the delivery of the strategic objectives. The draft document is based on the outputs of the joint seminar of the ICB Board and BNSSG strategic network at the end of March. The strategic framework was signed off by ICP in December 2022 and prioritisation of core objectives is underway. CB highlighted that feedback was that the current draft was too narrow and needs to reflect issues such as prevention, workforce challenges, service sustainability and access and use an asset-based approach. CB advised that an Editorial Board has been set up within the ICB which is working on version 2.0.	
	ED asked Executive members for an update regarding the Health and Care Improvement Groups as they are a key vehicle for delivery. LM stated that the first two Heath and Care Improvement Groups which are Primary and Community and Mental Health and Learning Disabilities will be meeting in May and focus on Terms of Reference and governance. Primary and Community will be chaired by Ruth Taylor and Julie Sharma and Mental Health and Learning Disabilities will be chaired by Jo Walker and Dominic Hardisty. The groups will report into the system Chief Executive Group and assurance will be through this committee and ICB Board.	

	Item	Action
	JH stated to the group that early diagnosis and prevention is what the system has aspired to but whilst the number of acute care consultants have increased over the years there has been a decrease both nationally and locally in General Practice, despite recruitment, so if early diagnosis and disease prevention is part of the strategic plan then allocation of resource will need to be addressed. JM discussed that prevention is included in the long-term plan and we need to show progress and its prevention of smoking, weight management, obesity, alcohol and drug misuse. JM explained that JM and Directors of Public health are doing a piece of work on how we manage some of the wide cross cutting prevention and the good news is that there is finance allocated for health inequalities. CB thanked committee members for ongoing engagement and informed colleagues the second draft of the strategy will be distributed in the middle of May and then to ICB Board in June. JF stated that we should try and confine the strategy into what to do in BNSSG as a system there are emerging issues that are being discussed and we have intervention from outside of our system and as chair of ICB Board JF wants to have a clear sight.	
	ED thanked CB for attending committee and welcomed further updates at committee.	
6.2	BNSSG Maternity - Update RS provided context of the maternity update being to ensure a clear line of sight with regards to quality and safety of maternity services through to the ICB Board, as recommended in the Ockenden review. She introduced Layla Toomer who is the Patient Safety Lead for Maternity and Neonatology and who joined BNSSG ICB in January 2023.RS asked LT to report on her first ninety days in BNSSG regarding maternity and neonatology services. RS also confirmed to the group that this did not include RUH at Bath as comes under Swindon and Wiltshire. LT explained that she attended the maternity and neonatal summit in Leeds in March which set the strategic direction for maternity services for the next three years. LT presented slides to the group which included the below key highlights:	
	 Acknowledgement of the amazing work delivered through the LMNS transformation programme and the good position of BNSSG as it is already progressing all areas outlined in the Single Delivery Plan and is leading in some areas. Stillbirth rates continue to reduce nationally. Concerning increase in suicide in postnatal period. Equity and equality front and centre to ensure we centre care around the most vulnerable. Strong emphasis of strengthening quadrumvirate working and the joint working across maternity and neonatology Service user voice needs to be amplified. 	

Item
Maternity Voices Partners to include neonatology and become Maternity and
Neonatology Voices Partners
 Changing culture – safe, supportive and learning.
Right workforce, right place, right time, right funding.
LT advised committee that the LMNS is developing a maternal death overview process which BNSSG are leading on for the Southwest. JM asked LT if there was any insight into maternal death rates in the black and ethnic minority community as a recent headline was that four times as many black and ethnic minority mothers die during pregnancy and childbirth than white mothers and any information regarding teenage mothers. LT confirmed will review data regarding teenage mothers and feed back to committee but regarding black and ethnic minority, work is being carried out at NBT and once finished a deep dive will take place and information will be presented at committee. RS assured committee members that every maternal death is investigated fully by the trust and each of those investigation outcomes is reviewed by our LMNS Consultant Obstetrician along with LT and the LMNS Patient Safety Group.
Consultant Obstetholan along with Er and the Elwider allont Salety Group.
LT discussed the Single Delivery Plan brings together actions from Ockenden, East Kent, Long Term Plan and Maternity Programme and the four main chapters were the following:
 Listening to and working with women and families with compassion.
 Growing, retaining, and supporting our workforce.
 Developing a culture of safety, learning and support.
 Standards and structures that underpin safer, more personalised, and more equitable care.
LT is working on a BNSSG dashboard which will give an overview of where we are and where we benchmark as a system. LT explained that UHBW go live with a new patient record system, BadgerNet in July and UHBW will be live in September, and this will improve the quality of data. LT then discussed the Saving Babies Lives Care Bundle v2, V3 has been delayed by NHS England. The five elements listed below are the what the maternity system is working towards:
1. Reducing smoking in pregnancy
 Preducing shoking in pregnancy Foetal growth: risk assessment, surveillance and management
3. Raising awareness of reduced foetal movement
4. Foetal monitoring in labour
5. Reducing preterm births and optimising perinatal care
6. Management of pre-existing Diabetes in pregnancy
LT picked key issues from the slide deck:

	Item	Action
	 Maternal death data within the slide pack was from January and February 2023 showing an increase of maternal deaths linked to blood clots on the lung and leg not just in BNSSG, this is being seen nationally and a potential link to COVID being explored. A local guideline to reduce the risk has been developed. Laptops with 5G have been provided for community midwives and reported connection issues are being addressed. BNSSG NICU admission rate at term is 6% in February, this was almost synonymous with January (7%). Deep dive is underway within trusts. Work is being carried out within the trust regarding accessibility of maternity services of non-English speakers starting from booking the first appointment with midwife through to hospital then community. NBT was non-compliant with the Maternity Safety Incentive Scheme but have an action plan in place to resolve this which is shared at Trust Board and the LMNS. UHBW are fully compliant with the MSISNBT have been nominated for an award for work on bereavement care and pregnancy loss. One to one care in labour has improved. Permanent funding for the lead neonatal advanced nurse practitioner secured along with a band 7 governance role and an additional band 6 education role in NICU. UHBW's 2022 national maternity survey results saw an improvement in many areas when compared to the results from 2021. 	
	LT concluded that excellent examples of team working seen, work that's happening from a quality point of view is positive. BadgerNet is going to improve data collection, accuracy, and assurance of saving Baby's Lives V3. Area of concern is maternity triage within both NBT and UHBW but is being focused on and strategies put in place within the Trusts but may be noted in any upcoming CQC inspection. Links with neonatology colleagues need to be stronger which LT and RS are embedding with LMNS. ED thanked LT for an excellent presentation and assurance's regarding maternity within BNSSSG. LT to come back to future committee to update on CQC inspections and update regarding BadgerNet.	
	ACTION 89: LT to attend OPQ Committee to update post CQC inspections and Badgernet implementation.	
6.3	Cancer 2ww Referral/Consultant ED explained to committee members that cancer performance was discussed at ICB Board in April. Data shows 56% of patients in BNSSG were seen within 2WW compared to 86% nationally. ED requested assurance from ICB Cancer Lead and Head of Performance Planned Care at BNSSG ICB.	

<u> </u>				
	sed recovery of canc	•		
-	ecovery trajectories a	•	•	
-	reed with input from			
-	NHSE team. There		-	=
	on a 2 week wait can		-	•
Jalients	seen on a 2ww and 6	bu palitiway between	19/20 and 22/2	.3.
	19/20 Sept-Feb	22/23 Sept-Feb	Variance	% +/-
	15/20 500000	22/20 000000	Vallance	,,,,
2ww	22,605	24,766	+2161	+9.50%
62d	1,423	1,492	+69	+4.80%
GB state	d there are two para	meters which have h	een hiahliahted	
			anginginou	-
`ancor '	2 week wait- % of p	oonlo soon within t	wa waake (GP	to consultant
	-	eopie seen within t	wo weeks (GP	
appointr	,			
GB advis	sed the February per	formance against this	s target has rise	en by 8.8% to
65.15%.	There has been sust	ained improvement i	in Q3 and Q4 of	f 22/23. The
		•		
	oosition remains be	low the national targe	et of 93% and i	ust under 21% below
-	•	low the national targe	•	
he natio	nal average. The 2w	w performance in bre	east was low bu	it additional
he natio	nal average. The 2w	w performance in bre uch as -weekend mega	east was low bu	It additional e reductions in referra
he natio nvestmer demand e	nal average. The 2w nt in clinical capacity su enabled performance to	w performance in bre uch as -weekend mega b be recovered such th	east was low but a clinics alongside at the 2ww stand	It additional e reductions in referra dard was achieved in
he natio nvestmer demand e Decembe	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w	w performance in breat uch as -weekend mega to be recovered such th w performance has sin	east was low but a clinics alongside at the 2ww stand ice dropped sligh	It additional e reductions in referra dard was achieved in tly and was at 88% in
he natio nvestmer demand e Decembe he Febru	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate	w performance in breact uch as -weekend mega to be recovered such the w performance has sin the set to 11 people breach	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days).	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going
he natio nvestmer demand e Decembe he Febru	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w	w performance in breact uch as -weekend mega to be recovered such the w performance has sin the set to 11 people breach	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days).	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going
he natio nvestmer demand e Decembe he Febru forward is	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate	w performance in breact uch as -weekend mega to be recovered such the w performance has sin tes to 11 people breach ity to meet the demance	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days). d to ensure delive	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted
he natio nvestmer demand e Decembe he Febru forward is hat the r	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capac	w performance in breach as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day fa	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days). I to ensure delive ester diagnosis s	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS).
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p	w performance in breach as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demance 4 is on the 28-day far lans that meet the name	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days). d to ensure delive aster diagnosis s ational ambition	It additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is	nal average. The 2w the clinical capacity su anabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the	w performance in breach as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day far lans that meet the nar 2ww standard will be	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It o ensure delive easter diagnosis s ational ambition e removed as pa	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f	nal average. The 2w of in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the ocus on meeting the	w performance in breach uch as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day fat lans that meet the nat 2ww standard will be FDS. This focus on the	east was low but a clinics alongside bat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin	It additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci national focus in 23/2 ts have developed p anticipated that the ocus on meeting the an improved patient e	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demand 4 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on experience. This does	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should t we can discount the
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f	nal average. The 2w of in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the ocus on meeting the	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demand 4 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on experience. This does	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should t we can discount the
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star	nal average. The 2w the in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the ocus on meeting the an improved patient en dard but meeting thi	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance 4 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on experience. This does s should not be prior	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that itised over mee	It additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS.
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci national focus in 23/2 ts have developed p anticipated that the ocus on meeting the an improved patient e	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance 4 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on experience. This does s should not be prior	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that itised over mee	It additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS.
he natio nvestmer demand e Decembe he Febru forward is hat the r Both trus year. It is peing a f provide a 2ww star	nal average. The 2w the in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the ocus on meeting the an improved patient en dard but meeting thi	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance 4 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on experience. This does s should not be prior	east was low but a clinics alongside hat the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that itised over mee	It additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS.
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star Cancer (days fro	nal average. The 2w nt in clinical capacity su enabled performance to r 2022. The breast 2w ary data (which equate on maintaining capaci- national focus in 23/2 the have developed p anticipated that the ocus on meeting the an improved patient en dard but meeting thi 52 day wait - GP refer m GP referral.	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance et as on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does s should not be prior erral, where cancer	east was low but a clinics alongside hat the 2ww stand ing the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as part confirming/rulin s not mean that itised over mee	at additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS.
he natio nvestmer demand e Decembe he Febru forward is hat the r Both trus year. It is peing a f Drovide a 2ww star Cancer 6 days fro GB advis	nal average. The 2wr nt in clinical capacity su enabled performance to r 2022. The breast 2wr ary data (which equate on maintaining capaci- national focus in 23/2 the have developed p s anticipated that the ocus on meeting the an improved patient en dard but meeting thi 62 day wait - GP refe m GP referral. sed February 62 day	w performance in breach as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demance et as on the 28-day far lans that meet the nar 2ww standard will be FDS. This focus on the experience. This does is should not be prior erral, where cancer performance improve	east was low but a clinics alongside hat the 2ww stand ice dropped sligh ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that ritised over mee treatment sho ed by 11.2% rea	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should we can discount the sting the FDS. Fuld begin within 6 aching 54.33%
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star Cancer (days fro GB advis which is	nal average. The 2wr nt in clinical capacity su enabled performance to r 2022. The breast 2wr ary data (which equate on maintaining capaci- national focus in 23/2 sts have developed p anticipated that the ocus on meeting the an improved patient en- dard but meeting thi 62 day wait - GP refe m GP referral. sed February 62 day 3.8% below the natio	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance et as on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does s should not be prior erral, where cancer performance improve onal average and below	east was low but a clinics alongside at the 2ww stand ice dropped sligh ing the 14 days). It o ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that itised over mee treatment sho ed by 11.2% rea ow the standard	at additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should t we can discount the sting the FDS. Fuld begin within 6 2 aching 54.33% d threshold of 85%.
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f Drovide a 2ww star Cancer 6 days fro GB advis which is The 62-o	nal average. The 2wint in clinical capacity su enabled performance to r 2022. The breast 2win ary data (which equate on maintaining capaci- national focus in 23/2 its have developed p is anticipated that the ocus on meeting the an improved patient en- dard but meeting thi 62 day wait - GP reform GP referral. Sed February 62 day 3.8% below the national lay performance need	w performance in breach ach as -weekend mega b be recovered such the w performance has sin es to 11 people breach ity to meet the demand 24 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does a should not be prior erral, where cancer performance improve onal average and belo ds to be considered in	east was low but a clinics alongside ing the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as pa confirming/rulin s not mean that itised over mee treatment sho ed by 11.2% rea ow the standard in the context of	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS. Fuld begin within 6 aching 54.33% d threshold of 85%. f volume of backlog
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star Cancer 6 days fro GB advis which is The 62-o clearance	nal average. The 2wr at in clinical capacity su enabled performance to r 2022. The breast 2wr ary data (which equate on maintaining capaci- national focus in 23/2 ats have developed p anticipated that the ocus on meeting the an improved patient en- dard but meeting thi 52 day wait - GP refe m GP referral. Sed February 62 day 3.8% below the natio lay performance need e that has been achief	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does is should not be prior erral, where cancer performance improve onal average and below ds to be considered in eved in Q3&4 of 22/2	east was low but a clinics alongside ing the 2ww stand ing the 14 days). It to ensure delive aster diagnosis a ational ambition e removed as part confirming/rulin s not mean that itised over mee treatment sho ed by 11.2% reaction ow the standard in the context of 23, acknowledgi	at additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS. Fuld begin within 6 aching 54.33% d threshold of 85%. f volume of backlog ing that where
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f provide a 2ww star Cancer 6 days fro GB advis which is The 62-o clearance	nal average. The 2wint in clinical capacity su enabled performance to r 2022. The breast 2win ary data (which equate on maintaining capaci- national focus in 23/2 its have developed p is anticipated that the ocus on meeting the an improved patient en- dard but meeting thi 62 day wait - GP reform GP referral. Sed February 62 day 3.8% below the national lay performance need	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does is should not be prior erral, where cancer performance improve onal average and below ds to be considered in eved in Q3&4 of 22/2	east was low but a clinics alongside ing the 2ww stand ing the 14 days). It to ensure delive aster diagnosis a ational ambition e removed as part confirming/rulin s not mean that itised over mee treatment sho ed by 11.2% reaction ow the standard in the context of 23, acknowledgi	at additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS. Fuld begin within 6 aching 54.33% d threshold of 85%. f volume of backlog ing that where
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is peing a f Drovide a 2ww star Cancer (days fro GB advis which is The 62-o clearance activity is	nal average. The 2wr at in clinical capacity su enabled performance to r 2022. The breast 2wr ary data (which equate on maintaining capaci- national focus in 23/2 ats have developed p anticipated that the ocus on meeting the an improved patient en- dard but meeting thi 52 day wait - GP refe m GP referral. Sed February 62 day 3.8% below the natio lay performance need e that has been achief	w performance in breach as -weekend mega be recovered such the w performance has sin es to 11 people breach ity to meet the demand 24 is on the 28-day far lans that meet the nar 2ww standard will be FDS. This focus on experience. This does a should not be prior erral, where cancer performance improve onal average and belo ds to be considered in eved in Q3&4 of 22/2 the backlog, perform	east was low but a clinics alongside the 2ww stand ing the 14 days). It to ensure delive aster diagnosis s ational ambition e removed as part confirming/rulines not mean that itised over mee treatment sho ed by 11.2% reaction ow the standard in the context of 23, acknowledginance drops. The	It additional e reductions in referra dard was achieved in tly and was at 88% in The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS. Fuld begin within 6 % aching 54.33% d threshold of 85%. f volume of backlog ing that where his is because the
he natio nvestmer demand e Decembe he Febru orward is hat the r Both trus year. It is Deing a f Drovide a 2ww star Cancer 6 days fro GB advis which is The 62-o clearance activity is Derforma	nal average. The 2wint in clinical capacity su enabled performance to r 2022. The breast 2wint ary data (which equate on maintaining capacity national focus in 23/2 ats have developed p s anticipated that the ocus on meeting the an improved patient endard but meeting this 52 day wait - GP reform GP referral. Sed February 62 day 3.8% below the nation lay performance need that has been achies focused on clearing	w performance in breach obe recovered such the w performance has sin es to 11 people breach ity to meet the demance 24 is on the 28-day far lans that meet the na 2ww standard will be FDS. This focus on the experience. This does is should not be prior erral, where cancer performance improve onal average and below dis to be considered in eved in Q3&4 of 22/2 the backlog, perform at the number of peop	east was low but a clinics alongside at the 2ww stand ice dropped sligh ing the 14 days). It o ensure delive aster diagnosis a ational ambition e removed as part confirming/rulin s not mean that itised over mee treatment sho ed by 11.2% rea- ow the standard in the context of 23, acknowledgi nance drops. The ple seen/treated	at additional e reductions in referra dard was achieved in tly and was at 88% in . The focus going ery. It was highlighted standard (FDS). s for the coming atient pathways are g out cancer should twe can discount the sting the FDS. Fuld begin within 6 aching 54.33% d threshold of 85%. f volume of backlog ing that where his is because the d within the wait time

2022 the system peaked at 1161 patients >62days on the PTL. From this point there has been a sustained improvement trend and the 22/23-year end position was 319

Item	Action
patients >62days on the PTL which is better than the nationally set targets and plan trajectories for both Trusts.	
 GB explained there is work across many pathways to improve performance with recruitment of locum and substantive workforce as well as use of any qualified provider (AQP) capacity. The system actions are directed to the most challenged pathways for example. The system dermatology group is working to improve the pathway for patients referred with possible skin cancer with a focus on image capture to enable remote dermatology assessment. Increased use of qFit testing in primary care is supporting primary care clinicians to not refer patients for lower GI investigation due to the high level of sensitivity of this test for CRC in certain patient groups. Gynaecology have invested in additional hysteroscopes and are working on improved information to support patients to be managed outside of the cancer pathway where appropriate. 	
There continues to be significant focus on, and improvement in, cancer performance with an expectation of continued improvement against the agreed trajectories. With an aging population and the widely acknowledged workforce challenges there is a need to identify areas in which productivity can be improved which includes booking and utilisation of slots in endoscopy, productivity in diagnostics and surgery as well as in histopathology and outpatient's services. The support for this focus on productivity would be welcomed with expected improvement in outcomes for patients both on cancer and non-cancer pathways.	
JM confirmed that assurance was given from a 2ww pathway referral perspective, but the 62-day target assurance is in the paper from GB and DS with proposals in summary.	
LM advised that pathway redesign in dermatology is needed to create sustainable improvement, and this is currently work in progress supported by the transformation team. GB advised of the significant work underway upskilling primary care colleagues and the use of dermatoscopes to reduce the number of unnecessary referrals. ED asked GB if there is any support that committee can provide. GB responded that there is positive support from relevant stakeholders, so no further support required from committee at the moment.	
SW asked GB and DS what work was underway to measure equalities, inequalities, and access to services. GB described the work of the BNSSG Cancer Inequalities group where the focus has been on early diagnosis, symptom awareness, screening and access through primary care and onward referral mapped to the 2ww pathway. DS advised work was underway to map health inequality breakdown within waiting lists but acknowledged further work to be undertaken with this.	

	Item	Action
	ED thenked CD and DC for attending committee to provide accurance and noted the	
	ED thanked GB and DS for attending committee to provide assurance and noted the significant improvement in breast cancer performance. GB and DS will update re dermatology at a future committee meeting.	
6.4	Joint Forward Plan LM described how the Joint Forward Plan provides the linkages between the system strategy, the Long-Term Plan, the strategies of the Health and Wellbeing Boards and the ICS strategy. The operational plan spans our key deliverables for 23/24 and the monitoring arrangements for the 35 key measures which have been set nationally for all systems. The plan will be reported through to this committee and on to ICB Board. LM advised that the Health and Care Improvement groups will drive improvement in the metrics that relate to their work areas and support progress against the Joint Forward Plan and the Long-Term Plan. SW advised of work underway to review and revise the outcome metrics for the system which is being led by Directors of Public Health. ED asked that the Operational Plan to be added to the agenda for May committee.	
6.5	 AWP- Action 29a Update RS gave an update regarding progress with the section 29a improvement notice issued to AWP by CQC on 24th January 2023. The first Quality Improvement Group (QIG) is taking place on Tuesday 2nd May, stood up in accordance with National Quality Board guidance. The QIG will be in place until members are assured that improvement and processes have been. SJ outlined the approach that AWP are taking to deliver the improvement needed. SJ advised that weekly insight meetings are taking place where a three-stage process of checking that improvement has taken place and is being embedded. There has been support from ICB, trust and NHS England colleagues to provide robust assurance that the issues are being addressed. SJ advised that AWP held a board meeting today and as part of that meeting a seminar was held where learning was explored. SJ stated AWP have reviewed the Well Led CQC approach and in future will be holding these reviews in May, June and July to support AWP learning and approach. RS will provide updates regarding progress via QIG. ED thanked SJ and PC for attending and given assurance to the committee on AWP approach and learning to date. ED was interested to learn about AWP board seminar and asked if subject could come to future committee meeting. 	
7	Committee Action Log	
	Action law undeted as attached	
8	Action log updated as attached. Items for information	
	8.1 LeDeR Q4 Activity Report	

	Item	Action
	RS stated that 82% people who are on Learning Disability registers in primary care have had their annual health checks in the 22/23 period and 98% of them had a health action plan, which is the highest performance in the Southwest and contributes to reducing the health inequalities being experienced by this vulnerable group.	
	 8.2 Quality & Performance Report including: CMDU Highlight Report Flu Highlight Report 8.3 BNSSG Area Prescribing Medicines Optimisation Committee (APMOC) 	
•	8.4 BNSSG ICS Infection, Prevention & Management Strategic Group (IPaMS)	
9	AOB	
	High court have made decision that the RCN nurse strike must end at midnight on Monday 1 st May.	
	Date of next meeting: Thursday 25 th May, 1400-1625	

Jodie Stephens

Executive PA April 2023





BNSSG Outcomes, Quality and Performance Committee

Minutes of the meeting held on Thursday 25th May, 1400-1625, on MS Teams

Minutes

Present		
Ellen Donovan (Chair)	Non-Executive Member for Quality and Performance, BNSSG ICB	ED
Jeff Farrar	Chair, BNSSG ICB	JF
Joanne Medhurst	Chief Medical Officer, BNSSG ICB	JM
Rosi Shepherd	Chief Nursing Officer, BNSSG ICB	RS
Lisa Manson	Director of Performance and Delivery, BNSSG ICB	LM
Jonathon Hayes	Chair of General Practice Collaborative Board	JH
Sarah Weld	Director of Public Health, South Gloucestershire Council	SW
In attendance		
Denise Moorhouse	Deputy Chief Nursing Officer, BNSSG ICB	DM
Caroline Dawe (item 6.3)	Deputy Director of Performance and Delivery	CD
Ellie Wetz (item 6.1)	ICS Development Manager, BNSSG ICB	EW
Tina Mostert (notes)	Executive PA, BNSSG ICB	TM
Apologies		
Paul May	Non-Executive Director, Sirona	PM
Sue Balcombe	Non-Executive Director, UHBW	SB
Julie Sharma	Chief Executive, Sirona	JS
Sue Geary	Healthwatch	SG
Colin Bradbury	Director of Strategy, Partnerships and Population, BNSSG ICB	CB
Hugh Evans	Executive Director, Adults and Communities, BCC	HE

Item	Action
Welcome and Apologies	
Ellen Donovan (ED) welcomed attendees and apologies were noted as above.	
Declarations of Interest	
	Welcome and Apologies Ellen Donovan (ED) welcomed attendees and apologies were noted as above.

	Item	Action
	There were no new declarations of interest.	
3	Minutes of April 2023 meeting	
	Minutes of the previous meeting were agreed as a correct record with the following amendment:	
	Jonathon Hayes (JH) noted that the figure of 17% given on page 6 regarding numbers of GPs was anecdotal rather than official. Jo Medhurst (JM) added that the national figure was 4% reduction despite recruitment.	
	ACTION: TM to amend wording of minutes to reflect this clarification.	
	There were no matters arising from the minutes of the previous meeting.	
4	Committee Action Log	
	ED explained that only action 82 was due for this meeting. Lisa Manson (LM) updated that a meeting is set for this piece of work to be undertaken with Sarah Weld and Colin Bradbury. Rosi Shepherd (RS) requested that Saving Babies' Lives be included in future Performance reporting. A full set of Maternity metrics is available by Trust but not by System. Layla Toomer is working with BI to obtain this feed into the design work being undertaken by Debs EI-Sayed (DES). ED queried whether this should therefore be a separate action. There was a discussion about disaggregating the data and LM suggested returning to OQPC with a proposal for reporting, noting that the Children's metrics are included in the baseline data but that the information supplied for this meeting has been extracted to give total numbers. Sarah Weld (SW) reported that SGC have completed a detailed Children's and Young People (CYP) Needs Assessment and that the data mapping could be useful.	
	ACTION 90: LM/RS to bring proposal to future OQPC regarding reporting Children's data, and outcomes with the assistance of SW.	
5	CNO/CMO Update	
	ED requested that the CNO report include updates on MRSA, and Endoscopy. Also, that the CMO report update on Virtual Wards (VW) and occupancy levels regarding learning lessons prior to the next winter planning beginning.	

Item	Action
 RS reported that there are no new and emerging risks. Regarding providers and current enhanced surveillance: Kewstoke is doing well and the view from the ICB Health Partners and the CQC is that they can step out of enhanced surveillance in July and return to Business as Usual (BAU). The Sherwood Lodge enhanced surveillance is being led by Dorset ICB. The situation there is improving and the improvements now need to be embedded in BAU. Ezec are being overseen through contract meetings. AWP had their first Quality Improvement Group following the CQC Poor rating for the Section 29A Ward Service, which was a positive meeting. RS reported that the CDiff situation is stable. MRSA rates are decreasing but will still be reported as Red as the threshold is zero. Work has been undertaken in the community to assess the impact of intravenous drug users being issued with Chlorohexidine Wipes and an update can be brought to OQPC when it is ready. The low incidence of MRSA infections means that a slight shift can skew the overall trend. JM added that there are no concerns being raised about MRSA regionally or nationally. 	
SW highlighted the Southwest Infection Control Conference where it was noted that there is a risk in the ongoing funding for community infection prevention and control, as the BNSSG team which is funded by LAs from Public Health budgets and is hosted by the ICB, is only funded to March 2024.	
JM added that the Level 3 status invoked during COVID has reverted to Level 2.	
JM reported that there have been cases of Avian Bird Flu in humans which is an area of focus for the UKHSA teams. It appears to have a low level of infectivity and low pathology. There have been no cases in the Southwest.	
RS reported that the RCN are out to ballot for further strike action between June and December which would be an all-out strike not by employer as previously. There will be no overlap with the June Junior Doctors Strike. RS described the frustration of the workforce both those that wish to take industrial action or those that are unable to. JM added that consultants have also been balloted on strike action and that the cumulative effect would be significant.	
JM reported that utilisation and numbers of beds in Virtual Wards (VW) in the Southwest are below the national trajectory. This was discussed at the MD group and Sirona are bringing VW leads into a meeting on 30.5.23. Initial indications are that there are multiple factors having an impact. This has received national attention and the regional MD is being held to account to investigate whether it is justifiable and reasonable.	

Item	Ac
 LM commented that three issues are having a Capacity is being affected by being beh the system has agreed to recruit substa MADE events and Industrial Action hav confidence in VWs. Clinical champions uptake. Using the wards for prevention of admis 	ind the recruitment trajectory and intial roles. e highlighted the lack of clinical on the wards result in a higher ssion as much as discharge
without admitting patients purely to ach JM explained that Dave Jarrett (DJ) is the SRC remit of integrated care. JM will prepare a brie OPQC.	D for VW as they are within the
LM noted that the VW are part of the overall w such are normally discussed in Discharge Gro Escalation Group (WEG)	
ACTION 91: JM / DJ to brief OPQC in July of	on VW under-utilisation
LM advised that Endoscopy is the most challe Significant capacity was lost during COVID be use of endoscopy areas for recovery. Endosco initial diagnosis followed by monitoring. There capacity and improve productivity. The suites expanded and the community diagnostic progr capacity.	cause of IPC restrictions and the opy is twofold demand with the is a programme of work to expand at the BRI and NBT have been
ED asked if there is a set of milestones to means a system challenge. LM explained that end elective oversight group.	•
ED suggested a briefing on endoscopy and ut	ilisation of the CDC in the Autumn.
JH queried why organisations such as Prime a wait referrals. LM advised that the national gui the referrals since the independent sector doe accreditation. Clinical infrastructure is also a lin sector, so accreditation is not an option. ED qu using independent providers. LM noted that th structured and that it would need an understar Prime Endoscopy Model and CDC.	dance limits those able to accept s not have the correct level of miting factor in the independent ueried whether other systems are ere is not anything that is

	Item	Action
	ACTION 92: LM to bring briefing paper to OQPC in September on Endoscopy and utilisation of the CDC.	
	JM gave a verbal update from HCPE explaining that the meetings would be monthly rather than fortnightly going forward. The mid-May meeting was used to put clinical input into the Joint Forward Plan (JFP), and to receive a presentation from NBT and UHBW on inequalities and elective care. This will build on the work to have a systems inequalities group. The meeting this morning discussed mortality data, which will be brought to OQPC in June / July and setting up a mortality surveillance group. Draft TORs have gone out for comment. There was a general debate about the digital strategy and shared access to data being a good enabler of care. Additional meetings will be a quarterly face to face session to create long term prevention commitments, starting with smoking. JM summarised that there is lots of work underway in multiple places.	
	ACTION 93: RS/ JM to meet with Ellie Wetz / Nic Saunders to bring an overview of the work and clinical leadership decision making process to a future OPQC, tying it into the work on Risk Matrices from the last workshop. ACTION 94: JM will present written update om smoking prevention workshop as part of June's report.	
5.1	Director of Performance & Delivery	
	Performance Data	
	 LM highlighted the following points: A&E performance is improving and either on, or exceeding, target. Progress is being made in Urgent Care, through a combination of different pathways and demand being more manageable. 12-hour trolley waits have been reduced Ambulance performance is improving and is routinely within 30 minutes. The next focus is to get it to 18 minutes. Elective achieved the end of year targets for 104 and 72 week waits. Breaches on 104-week waits are due to patient choice, predominately in children's or a patient requesting a particular consultant. Mutual aid is being investigated for specialist surgery. 	
	 Work will be undertaken through this year's plan to reduce all waits further. BNSSG is an outlier in the inclusion of data on choice in reporting, but it is 	



	Item	Action
	 Improvements are being seen in cancer, particularly for breast and urology. Increasing issue regarding dermatology for 2-week waits and treatment incl surgery, however the faster diagnosis standard for this year will be achieved and this is the overarching target that we are monitoring against. Achievement of the Dementia Diagnosis Rate but this is mainly based around Bristol, so a programme of work is needed to redesign services for the whole of BNSSG. Achieving the range of MH standards but still need to look at inappropriate placements. Access rates for Children's and Young People's MH have been improving but the satisfaction rating is not seeing a corresponding improvement. 	
	 RS requested clarification about mixed sex accommodation as NBT and UHBW score cards indicate that there is none. LM advised that this reporting ceased in 2020 but that the scorecards have not been revisited to remove it. ED asked about the provision of care and safety and whether a concern should be raised about mixed-sex accommodation as it has a significant impact on the patient experience and was raised as a safety point in the AWP CQC inspection. RS agreed to take this to regional colleagues for discussion. ACTION 95: RS to discuss mixed-sex accommodation with regional colleagues and report back to OQPC. 	
	LM reported that significant progress had been made on Out of Area placements for AWP and that this continues to be a focus of work to ensure clear and rational reasons for using them and clear therapeutic pathways. The aim is to prevent people being placed for long stays, so the data is being reviewed daily. It has been identified that some patients are delayed in discharge due to lack of accommodation and wrap around support in the community. AWP needs to run at a lower bed occupancy in order to manage discharges proactively. James Eldridge is leading work this year, equivalent to the D2A programme in physical health, to ensure patients are going to the correct physical place upon discharge from AWP.	
6.1	 Health and Care Improvement Groups Mental Health Primary Care and Community LM noted that the Children's HCIG has had its first meeting. 	

Item	Action
 EW was introduced to the meeting and explained that her purpose was to provide understanding of the process and how HCIGs are working. EW confirmed that the Acutes HCIG has yet to meet so LM is meeting with SD, Maria Kane, and Eugine Yafele on 2/5/23 to organise it. EW presented the following points: The Initial meetings of each HCIG have been treated as soft launches and have invited all who were on previous meeting circulations. The next stage of the decision-making framework will go to Board in July and will describe the decision-making authority conferred on HCIGs and their members. The substructure beneath the HCIGs will filter what goes to the HCIGs to enable them to ensure that the system functions. There has been a standardised agenda to reflect on TORs, give opportunity to have a deep dive into the purpose of the HCIG and its role in the ICS. The HCIGs are intended to have system oversight to ensure that system partners work together collectively to undertake operational plans and achieve strategic objectives. They are driven by the principle of person-centred improvements in population health. There are two partner chairs for each HCIG, all being Chief Execs except for Childrens which is still being worked through. 	
 Actions previously sitting with the groups which have now become the HCIGs have been taken forward. At each group which has already met the following points were discussed: Level and representation of membership. Currently the existing steering groups have been utilised with their broad memberships, but it is expected that this will be refined with some attending the Subgroups. The role of the locality partnerships and how they will fit in. The role of the transformation hub and SDUs in support of HCIGs. HCIGs needing an overview of system risk how this will fit with SQG. ICB support for HCIGs with the assets already in the system such as BI. LM noted that work is underway to map information and data which will go to each sub-group so that none is lost. HCIGs will be used to escalate and unblock issues and prioritise strategy within their areas. The Acutes HCIG may be different as the intention is to keep most of the work out of the hospital space. 	
and asked about understanding of the interaction between and with committees.	



	Item	Action
	LM explained that the balance will be correct when we recognise that committees are there to provide assurance to Board and HCIGs are the executive function which takes action. HCIGs are not for assurance but are for making sure transformation is happening and issues around quality are being raised. Committees can task HCIGs to take forward work. This will mean that some things will be duplicated in order to provide assurance to Board. Regarding the underpinning structure, the important issue is to ensure that conversations happen about pathways and between HCIGs for overlapping issues. LM noted that part of the process for developing new ways of working is for things to go wrong as they are tested. ED requested a report back to OPQC as the HCIGs progress and unlock the understanding of how they will function. ACTION 96: LM to report back to OPQC on development of HCIGs.	
6.2	Childrens Services	
	Childrens Performance Data	
	 ED noted that there had been a challenge from Julie Sharma (JS) at Board about sufficient consideration being given to children's services at OQPC reporting. LM reported the following points: The dashboard brought to this meeting highlights where there are issues in children's and that they are part of the total data, rather than being isolated. RTT performance in key areas has been shown in terms of commission. Community paediatrics is a challenge as is paediatrics in the acutes. It is hard to recruit to community paediatricians, so it is not possible to solve the challenge by simple expansion of services. Investments have been made in Community Therapies in North Somerset to expand the portfolio so that children are seen within the 18-week standard. There has been year-on-year investment in CAMHS with 71% of CAMHS referrals now being seen within 18 weeks. However, the feedback from families is that it is difficult to be seen so there is a disconnect between the data and the experience. A deep dive is underway to understand this and find out if it is partly due to the change in criteria. All of the headline metrics point to improved access. Data is fed into Children's Operational Delivery Board for oversight, along with input from parent carer forums at SEND which gives real time feedback. 	

Item	Action
ED asked about the scale of the community paediatrics challenge, what it means and what other systems are doing to address the issues. LM commented on the work which is being done on redesign of the autism pathway, prioritising more urgent referrals over routine. Sirona have plans for dedicated community paediatricians associated with SEND in each area. Recruitment drives have not solved the issues so Sirona are working on redesigning the role to ensure that paediatricians are only doing what they alone can do. This is expected to be challenging.	
JH noted that it is hard to monitor consequences of the service not being able to deliver, and hidden activity which happens elsewhere in the system. Harm is caused because of delay and patients spill into primary care.	
LM added that elective delays have a resulting effect on other parts of the system so children should be able to utilise different parts of the system in parallel rather than sequentially. LM explained that the work is currently going through the gateway process and is in Gateway 0 for the discovery phase, looking at other places and systems. LM is the lead for Children performance and DES is the lead for Transformation.	
RS queried the information on the slide deck which shows paediatrics in totality rather than by specialty as would happen with adult services noting that, if it were broken down it would be easier to understand where reinvestment is needed. LM advised that the elective waiting list for Children is monitored by individual speciality and sub-speciality and that this shows that the biggest wait in Children's is for dentistry, so action is being taken to both recruit specialists and to send patients out of area for surgery so that they are treated in a timely way. However, the information shared at this meeting has been collated to bring a summary dashboard. Weekly conversations take place with the national team at the detailed level of individual children. However, that level of visibility is not available in community paediatrics. Previous iterations of the dashboard have shown the splits and the data is available.	
LM noted a concern about the growth in referrals over waits and that they represent a different mixture of issues.	
RS highlighted that HCPE want to understand the changing morbidity of children so that the system can make planning decisions to prevent further deterioration as they become adults to mitigate future risks. RS also noted the necessity of understanding the different data sets needed at Committees and HCIGs.	

Item	Action
JH commented on the secondary care dental waits asking if performance data were available from community dentistry and LM confirmed that it would be available in the future.	
LM asked that OQPC task the Children's HCIG to determine and obtain the data which needs to come to committee and investigate cross-cutting themes, giving the example of Children's access to NHS dentistry being a cause of the requirement for Secondary Dentistry services, and that Dentistry is technically overseen by the Community HCIG.	
LM reported that CAMHS and continence have not been included in the data and noted that some of the increase in waiting list could be due to cleaner data and the increase in referrals.	
JM referred to the email received from JS regarding the data context and that part of the picture is about the story behind the issue. JM highlighted that the OQPC need to be part of the story, so background information is needed to gain a wider picture before narrowing down into a consensus of top concern and noted that Charlie Kenward is leading work on this.	
LM suggested that education and social care should be included in collection of data, particularly for immunisations. LM asked the OQQC to task the HCIG to work to gain a clear understanding of the information needed. For example, a key issue is the ability to access MH services which affects feedback, access rates and is creating a steady trend of children into ED via 111 and 999	
ED suggested a debate outside committee between the execs and data teams to ensure no duplication. ED requested that the execs have a conversation with SD to determine the right way to progress this and bring back to OPQC in the Autumn. LM added that it should be a wider system conversation to consider other aspects of Childrens work.	
Jeff Farrar (JF) reflected on the conversation at the away-day regarding scrutiny at committee and the necessity of a conversation by exec members prior to committee, so that a united voice is given by those delivering the service. JM reported that different questions are being asked of execs by different people during this period of working out the relationships between Chief Execs, whose thinking is still evolving and emerging. Since HCIGs have only met once questions do not have clarity or focus yet. JM also noted that the committee structure can be used for leverage. JM identified the need for Key Lines of Enquiry (KLOEs) for OPQC and understanding of the reason and background for questions being asked. RS noted that, as HCIGs develop, they will have more focus and direction.	



	Item	Action
	LM highlighted that Children's is equivalent to adults but there is only one HCIG for Children's and three for adults.	
	ACTION 97: LM HCIG and OPQC to have oversight of children's work and progress to be brought back to committee later in the year.	
6.3	Operational Plan – Update Flow Indicators 	
	Caroline Dawe (CD) explained that there are thirty-five key metrics to be monitored which have been set at a national level and a funding profile to work through. The Operational Plan attempts to give clarity to the work of the ICB and where there are gaps in system provision or performance. It includes a clear statement regarding the information available and should allow BNSSG to return to Segment 2 as a system and by provider. The plan highlights where BNSSG are not achieving against 92% bed occupancy, over 65-week elective care waits (although these have an agreed plan) and the 75% early diagnosis ambition for cancer waits.	
	JH asked for clarification on UDAs being categorised as green when there is not data available yet. LM explained that this is in line with transfer of 22/23 performance on delegation from NHS England. In regard to ARRS – for 22/23, BNSSG drew down all of our Additional Roles Reimbursement Scheme (ARRS) funding, so we have all of the ARRS in place, but we are only reporting on month one. LM noted that some sections are only reported on annually in line with the Operational Data Definitions. However, the Operational Plan will return to OPQC monthly for oversight of delivery and challenges.	
	ED raised the issue of there only being two metrics for health inequalities. LM commented that those are the metrics used in the national plan and that, as an ICB, we can decide to delivery against additional ones. In the NHS 23-24 objectives there are three metrics within the domain of Health Inequalities, two focus on the management of hypertension and lipid lowering therapies. JM added that those metrics drive the worst outcomes and excess mortality so could give the most impact quickly to increase life expectancy.	
	ED noted that both metrics are red. JM commented that these key strategic objectives will drive a campaign and there is lots of work underway. However, given the amount of work already done with little improvement seen, we need to go into an improvement cycle, and then a trajectory can be created.	
	ED asked if either needed escalation or added support from the committee. LM commented that it could be useful to do a deep dive into perinatal mental health which, although not being high profile, has a significant impact when it is not	

	Item	Action
	functioning. UHBW undertake some provision internally which has created a discrepancy. ED suggested a light touch briefing.	
	ACTION 98: LT to work with LM team to produce a timeframe for reporting back to OQPC on perinatal mental health.	
	JF highlighted the issue of the poorer outcomes for BAME women who are five times more likely to die during their pregnancy or childbirth. RS advised that the LMNS has an Equity and Equality Plan comes to the LMNS for reporting and can be included in the onward reporting to this committee.	
	LM suggested that, following the perinatal mental health work coming back to OQPC, JM suggested that in the future the committee could have focus on areas that have a high-volume impact such as hypertension, as part of a wider discussion on how best to design the committee agenda.	
	ACTION 99: JM will work on this with RS, LM and suggest a way forward to ED. To begin JM suggested a focus on hypertension- Adwoa Webber to action.	
	JH highlighted Primary Care and that historically there was data from some parts such as Out of Hours and Severnside but that data from GP practices has been more difficult to capture and collate. Practices are now seeing the benefit of sharing data to demonstrate where activity is happening and be able to direct resources to supporting service delivery across the wider system. Dentistry is a significant concern in BNSSG, with a deficit in Primary Care service delivery exacerbated by inequalities, which has a knock-on effect on secondary care demand.	
	ED asked for clarification about measuring against the four high level objectives in the operational plan. LM responded that those are high level objectives and that the HCIGs will have a set of nested metrics to include work underway in terms of Primary Care access and recovery plans including dentistry. Since dentistry is under the remit of DJ, OQPC will need a line of sight and clarification of which committee it reports to.	
	ED reported that this committee will move to bi-monthly from September and on the alternate months ED will sit on Primary Care Committee to give all execs the opportunity to attend both.	
	ACTION 100 – RS / LM / JM / DJ to agree new process from September.	
7	Items for Information	

	Item	Action
	7.1 Customer Services & Complaints Quarterly Report 7.2 LeDeR Governance Group Minutes – April 7.3 System Quality Group Minutes - April 7.4 Health and Care Professional Executive Minutes - April All the documents were addressed on the agenda.	
8	 AOB Membership ED suggested a review of OQPC membership and the following points were raised: One DAS representing all 3 LAs. Timing and date of OPC Voluntary attendance for NEDs Co-opted attendance to cover specific items by execs. NEDS not being accountable for delivery but rather holding others in the system to account. Possibility of another Chief Nurse from within the system joining on a rotating basis. The necessity of being different to performance committees in place within the acutes, by looking at issues which can only be solved as a collective. Ensuring the agenda is appropriate for the audience. ACTION 100: JF, ED, RS, JM and LM to bring to discussion at further 	
Ting	meeting. Date of next meeting: Wednesday 28 th June 1300-1525	

Tina Mostert Executive PA May 2023

